Regulation of Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance through Modulation of Immune Cell Function by Ying, Wei
REGULATION OF OBESITY-INDUCED ADIPOSE TISSUE 
INFLAMMATION AND INSULIN RESISTANCE THROUGH 
MODULATION OF IMMUNE CELL FUNCTION 
 
A Dissertation 
by 
WEI YING 
 
Submitted to the Office of Graduate and Professional Studies of  
Texas A&M University  
in partial fulfillment of the requirement for the degree of  
 
DOCTOR OF PHILOSOPHY 
 
Chair of Committee,              Fuller W. Bazer 
Co-Chair of Committee,        Beiyan Zhou 
Committee Members,           Guoyao Wu 
                                              Stephen H. Safe 
                                              Robert S. Chapkin 
                                              Kathrin A. Dunlap 
Head of Department,            Russell H. Cross 
 
May 2015 
 
Major Subject: Animal Science 
 
Copyright 2015 Wei Ying
 
 
ABSTRACT 
The recruitment of immune cells into adipose tissue is a hallmark of 
obesity and a key event contributing to the development of adipose tissue 
inflammation and insulin resistance. However, the mechanisms regulating 
functions of immune cells in adipose tissue niches in response to obesity are 
poorly understood. In the present studies, I have demonstrated that 
hematopoietic-specific microRNAs and a functional cytokine, interferon tau, act 
as critical regulators for activation of adipose tissue resident immune cells 
including macrophages and B cells which subsequently affect obesity-induced 
tissue inflammation and insulin resistance. 
First, miR-150KO mice display exacerbated obesity-induced tissue 
inflammation and insulin resistance. This phenotype is recapitulated by the 
adoptive transplantation of isolated miR-150KO B cells from obese mice into 
mice lacking B lineage cells. Further, miR-150KO B cells exerted potent 
stimulatory effects on both T cells and macrophages. Several miR-150 target 
genes were identified and knockdown of those genes individually or in 
combination alleviated B cell actions upon stimulation by altering important 
pathways downstream of the B cell receptor complex.  
Second, I have shown that miR-223 is a critical mediator for PPARγ 
action in controlling M2 activation, and subsequent beneficial effects that 
mitigate tissue inflammation and insulin resistance. Impaired PPARγ functions 
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were observed in miR-223KO mice with respect to suppression of inflammation 
and insulin sensitivity. Disruption of miR-223 in macrophages impaired PPARγ-
dependent M2 activation, whereas overexpression of miR-223 further enhanced 
PPARγ-mediated M2 activation. miR-223 is a PPARγ-induced gene during M2 
activation as confirmed by chromatin immunoprecipitation analysis and 
luciferase reporter assays. Two new miR-223 target genes Rasa1 and Nfat5 are 
crucial regulators of M2 activation via the PPARγ-miR-223 axis.  
Third, using a diet-induced obese mouse model, I discovered enhanced 
insulin sensitivity in obese mice administered IFNT compared to control mice, 
and this was accompanied by a significant decrease in secretion of 
proinflammatory cytokines and an increase in M2 macrophages in adipose 
tissue. Further studies revealed that IFNT is a potent regulator of macrophage 
activation that favors M2 responses.  
Collectively, the findings from these thesis studies open a window to the 
development of novel therapeutic strategies to mitigate obesity-related diseases. 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
Introduction 
Insulin resistance is the key etiology contributing to the development of 
metabolic syndrome.1 A prolonged state of metabolic syndrome contributes to 
the development of type 2 diabetes mellitus (T2DM) that is also a major cause of 
various complications such as stroke, heart diseases, kidney failure, and 
blindness. Over the past several decades, obesity is now an epidemic and has 
become one of the most common causes of in insulin resistance. In parallel, 
there has been a dramatic increase in the incidence of T2DM. Indeed, in the 
United States, about 29.1 million people or 9.3% of the population have type 2 
diabetes, and more than 80% of people with T2DM are overweight (BMI>25).2  
As a hallmark of obesity, chronic low-grade tissue inflammation is one of 
the major contributors to the pathogenesis of insulin resistance.3-5 Other 
metabolic abnormalities such as adipose tissue hypoxia, lipotoxicity, 
endoplasmic reticulum stress and mitochondrial dysfunction ultimately converge 
in the development of tissue inflammation in the context of obesity. 
Inflammatory signaling in adipose tissue 
Visceral adipose tissues (VATs) are one of the major sites producing and 
releasing inflammatory cytokines, which extend beyond tumor necrosis factor α 
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 (TNFα), interleukin 1 β (IL1β), IL6, and interferon γ (IFNγ).3,4 The signaling 
pathways governed by c-Jun N-terminal kinases (JNK) and nuclear factor kappa 
B (NFκB) exert profound impacts over production of these inflammatory 
cytokines by VATs in response to various stimuli (Figure 1.1).6,7 In response to 
the activation of toll-like receptors (TLRs) such as TLR2 or TLR4, the 
phosphorylation of the inhibitor of NFκB (IκB) leads to its dissociation from 
NFκB.8 The released p65 translocate into the nucleus where it binds to DNA 
response elements that induce expression of inflammatory molecules including 
proinflammatory cytokines. The phosphorylated IκB eventually undergoes 
degradation. In addition, adipocytes also express receptors for binding of 
inflammatory cytokines such as TNFα and IL1β, which can activate the JNK 
signaling pathway. The phosphorylation of JNK triggers the activities of 
transcription factor activator protein 1 (AP-1)-mediated signaling that 
subsequently drives the inflammatory responses including production of 
proinflammatory cytokines. Thus, these transcription factors act in an autocrine 
manner to promote inflammatory responses in adipocytes. In contrast, 
adipocytes also secret anti-inflammatory adipokines such as adiponectin that 
either directly suppress the activation of NFκB signaling pathway or trigger 
peroxisome proliferator-activated receptor-gamma (PPARγ) activation which 
represses production of inflammatory cytokines.9-11 In the context of obesity, the 
increased levels of TLR4 ligands such as free fatty acid significantly enhance the 
activities of the inflammatory signaling pathways mediated by JNK and NFκB in 
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 adipose tissues and this is accompanied by an increase in the release of 
inflammatory cytokines.12,13 Furthermore, obesity-induced hypoxia dysregulates 
production of adiponectin from adipocytes, which causes hypoadiponectinemia 
and ultimately impairs the negative controls of the inflammatory responses.14 
Mechanisms of inflammation-induced insulin resistance 
Insulin serves as a nutrient sensing hormone exhibiting diverse functions 
such as stimulation of nutrient uptake by cells to maintain energy homeostasis. 
The actions of insulin vary in distinct metabolic tissues. For example, in skeletal 
muscle insulin stimulates the translocation of glucose transporter type 4 (GLUT4) 
to the plasma membrane that facilitates glucose uptake, whereas insulin 
resistance impairs glucose uptake by skeletal muscle.15 Insulin action in liver 
suppresses gluconeogenesis by down-regulating expression of key 
gluconeogenic enzymes.16 A reduction in insulin sensitivity in liver leads to 
increased hepatic glucose production.17 In adipose tissues, insulin has an anti-
lipolytic function via decreasing hormone sensitive lipase activity, subsequently 
inhibiting free fatty acid release from adipocytes.18 In contrast, insulin resistance 
promotes the circulating concentrations of free fatty acids, which can decrease 
insulin sensitivity in skeletal muscle by activating the serine/threonine kinase, 
protein kinase C-θ (PKCθ).19  
Insulin signaling involves a complex signaling cascade downstream of the 
insulin receptor.20 Upon the binding of insulin, activation of the insulin receptor 
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 enhances the phosphorylation of insulin receptor substrates 1-4 (IRS-1-4). The 
formation and activation of this insulin receptor complex activates the 
phosphatidylinositol 3-kinase (PI3K)-AKT and Ras-mitogen activated protein 
kinase (MAPK) pathways (Figure 1.1). The insulin-induced activation of the 
PI3K-AKT pathway leads to increased glucose uptake and suppression of 
gluconeogenesis, while the effects of insulin on mitogenesis and cell growth are 
mainly associated with the MAPK pathway activity. In addition, insulin stimulates 
cell growth and differentiation through activation of the PI3K-AKT and MAPK 
pathways. In addition to IRS-mediated insulin signaling, activation of insulin 
receptors also recruits and activates other insulin receptor substrates including 
src homology 2 containing protein (SHC) and growth factor receptor-bound 
protein 2 (Grb-2), which then triggers the Ras-MAPK signaling cascade.21 The 
phosphorylation of heterotrimeric G protein (Gαq/11) stimulates GLUT4-
mediated uptake of glucose by activation of the PI3K-AKT signaling pathway.22 
The formation of the adapter protein Cbl associated protein (CAP)/Cbl complex 
can stimulate translocation of GLUT4 to the cell membrane to facilitate glucose 
uptake.23  
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Figure 1.1 Inflammation signaling and insulin resistance. Activation of TLR2 
or TLR4 and/or tumor necrosis factor receptor (TNFR) induces NFκB and JNK 
signaling. The serine kinases IKKβ and JNK can phosphorylate IRS1 and IRS2, 
which suppress downstream insulin signaling including the PIK3/AKT pathway. 
In addition, activation of IKKβ leads to phosphorylation and degradation of the 
inhibitor of NFκB (IκB) that subsequently permits translocation of NFκB to the 
nucleus. Similarly, activation of JNK results in the formation of transcription 
factor activator protein 1 (AP-1). Ultimately, both nuclear NFκB and AP-1 induce 
the expression of proinflammatory cytokines, which can contribute to the 
development of insulin resistance. TLR, toll-like receptor; Myd88, myeloid 
differentiation primary response gene-88; TRIF, TIR domain containing adaptor 
protein inducing IFNγ; RIP, receptor interacting protein; TRADD, TNF receptor-
associated death domain; TRAF2, TNF receptor-associated factor 2; PIK3, 
phosphoinositide 3-kinase; NFκB, nuclear factor kappa B; JNK, c-Jun N-terminal 
kinases.  
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 Chronic low-grade tissue inflammation is a hallmark of obesity and a well-
known cause of obesity-induced insulin resistance through interrupting the 
insulin signaling in key metabolic organs such as white adipose tissue, liver and 
skeletal muscle. The inflammatory responses interrupt the insulin signaling 
pathway through several mechanisms in the context of obesity. For example, 
activation of JNK and IκB kinase β (IKKβ) can attenuate insulin signaling by 
directly inhibiting activation of the insulin receptor (Figure 1.1).24,25 In addition, 
the transcription factors NFκB and AP-1 exert transcriptional control on the 
expression of genes that encode key components of the insulin signaling 
pathway including GLUT4, IRS-1, and AKT.26-29 Inflammatory cytokines, such as 
TNFα, trigger the signaling that also interferes with insulin action through 
modulation of various metabolic pathways that promote production of free fatty 
acids that decrease insulin sensitivity.30,31 Additionally, inflammation induces 
expression of the key enzyme sphingomyelinase for synthesizing ceramide that 
suppresses activation of AKT, that is downstream of the insulin signaling 
pathway.31 
The link between tissue inflammation and metabolism 
A key common denominator between metabolism and inflammation lies in 
the balance between intracellular lipids such as ceramides and sphingolipids. 
Holland et al. revealed that saturated fatty acid-induced activation of TLR4 
signaling also up-regulates the biosynthesis of ceramide through activation of its 
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 downstream component IKKβ.31 However, under the stress of obesity, excessive 
activation of TLR4 signaling leads to the accumulation of ceramide in key 
metabolic tissues such as skeletal muscle, which impairs glucose uptake and 
eventually leads to insulin resistance.31 In contrast, knockout of TLR4 prevents 
the abnormal biosynthesis of ceramide and obesity-induced metabolic 
syndrome.31  
Interestingly, ceramide can activate adiponectin receptors and 
adiponectin promotes ceramidase activity and modulates the balance between 
ceramides and sphingosine-1-phosphate.32 These regulatory impacts of 
adiponectin on ceramide metabolism appear to be critical for multiple tissues, as 
it prevents apoptosis of cardiomyocytes and pancreatic β cells.32 In the context 
of obesity, the diminished level of adiponectin may account for the accumulation 
of ceramide.  
Obesity-induced adipocyte hypoxia 
During long-term excessive nutrient intake, adipocytes undergo 
hypertrophy and hyperplasia.33-35 In mice, the increase in adipose tissue mass is 
mainly due to the hypertrophy of adipocytes after 4 weeks of feeding a high fat 
diet (HFD), while prolonged HFD exposure leads to a significant increase in 
adipogenesis in epididymal adipose tissue, but minimal effects on adipogenesis 
in subcutaneous fat depots.33 The expansion of adipose tissue mass enhances 
lipid metabolism and the fatty acid flux that stimulates activation of adenine 
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 nucleotide translocase (ANT)-mediated uncoupling of respiration in adipocytes.36 
This increases oxygen consumption by adipocytes and induces relative cellular 
hypoxia that triggers expression of hypoxia-inducible factor 1α (HIF1α).36,37 
Upon the up-regulation of HIF1α expression in adipocytes, the production of 
chemokines such as chemokine (C-C motif) ligand 2 (CCL2) and leukotriene B4 
(LTB4) increases the recruitment of immune cells into white adipose tissues, 
whereas loss of HIF1α impairs secretion of these chemokine from adipocytes in 
response to hypoxia and prevents dramatic infiltration of immune cells.36,38 In 
addition, the transcriptional function of HIF1α on gene expression requires the 
ubiquitously expressed subunit aryl hydrocarbon nuclear translocator (ARNT or 
HIF1β) to form the heterodimer complex.39 Interestingly, HIF2α expression 
serves as the negative control to counteract HIF1α function in adipocytes.40,41 
There is a significant decrease in expression of HIF2α in adipocytes and loss of 
HIF2α in adipocytes promotes the inflammatory status of visceral fat depots in 
obese individuals.41 Thus, the hypoxia-induced HIF1α expression in adipocytes 
acts as the early trigger for inflammation in white adipose tissue (Figure 1.2). 
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Figure 1.2 Macrophage recruitment into visceral adipose tissue. In the 
obese state, adipocyte hypertrophy and apoptosis lead to the production and 
release of chemokines that induce the recruitment of monocytes into visceral 
adipose tissue. In response to inflammatory stimuli, the infiltrated monocytes 
further differentiate into proinflammatory M1 macrophages, which also secrete 
proinflammatory cytokines and promote the inflammatory responses in both 
autocrine and paracrine manners.  
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 Macrophage infiltration 
In response to chemokines released from the white adipose tissue, 
circulating monocytes/macrophages are recruited into white adipose tissues and 
become a major immune cell component in this niche. The adipose tissue 
macrophages (ATMs) have crucial functions including the removal of dead 
adipocytes.42,43 Indeed, the infiltrated macrophages aggregate and surround the 
dying adipocytes to form “crown-like structures”. In the context of obesity, ATMs 
account for up to 50% of the stromal cell population in VATs and exert profound 
impacts on adipocyte functions.41 
Among these chemokines, CCL2 can be produced by adipocytes and 
adipose tissue resident macrophages to exert profound effects on the 
recruitment of monocytes/macrophages into VATs (Figure 1.2).44 The 
accumulation of white adipose tissues is accompanied by an increase in the 
circulating level of CCL2, due to the enhanced HIF1α transcriptional 
functions.36,45 In the diet-induced obesity mouse model, the abundance of CCL2 
in VATs increases within the first week of HFD feeding, and the secretion of this 
chemokine into plasma is elevated after 4 weeks of feeding a HFD.46 In contrast, 
loss of CCL2 reduces the accumulation of ATMs, which eventually attenuates 
the obesity-associated adipose tissue inflammation and insulin resistance.47 
Ectopic expression of CCL2 from adipocytes is sufficient to enhance the 
accumulation of macrophages in VATs and to exacerbate insulin resistance of 
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 mice on either a normal chow diet or a HFD.48 The enhanced level of CCL2 
facilitates the recruitment of macrophages into visceral fat depots through 
interacting with the chemokine (C-C motif) receptor 2 (CCR2) expressed on 
macrophages.49,50 In response to plasma CCL2, Geissmann et al. indicate that 
the peripheral blood monocytes expressing CCR2 are recruited into the inflamed 
tissues where they differentiate into macrophages that promote inflammatory 
responses.51 Lumeng et al. identified recruited macrophages in visceral fat 
tissues using an inert fluorescent dye PKH26 that is efficiently taken up by 
phagocytic cells in vivo.52 They further demonstrated that the recruited CCR2+ 
macrophages into VATs exhibit greater inflammatory responses compared to 
resident macrophages in the context of obesity.52 However, the CCR2 deficiency 
does not significantly affect infiltration of macrophages into adipose tissue in the 
context of obesity,46 suggesting that there are other mechanisms involved 
recruiting these cells into the inflamed tissues. In addition, loss of CCR2 results 
in accumulation of undifferentiated myeloid cells that display inflammatory 
phenotypes in VATs during the time of feeding a HFD.48 
Recently, chemoattractant leukotrienes (LTs) have been identified as 
mediators controlling macrophage recruitment into white adipose tissue under 
obesity-induced stress.53 LTs are proinflammatory lipid mediators that can be 
rapidly released from activated leukocytes to promote migration of leukocytes 
into tissues.54,55 Adipocytes are a major cell type secreting this chemoattractant, 
and its expression in adipocytes isolated from VATs is up-regulated by leptin 
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 during obesity.53 The elevated levels of LTs contribute to recruitment of 
macrophages into VATs, whereas LT-deficient mice accumulate fewer ATMs in 
response to feeding a HFD.53 Thus, LTs play critical roles in regulating 
macrophage chemotaxis in the context of obesity. In response to LTs, circulating 
CD11b+ monocytes express the G protein-coupled receptor BLT-1 that is also 
induced in response to the HFD feeding.55,56 BLT-1 plays a critical role in the 
functions of LTs in inducing macrophage infiltration, as evidenced by decreased 
accumulation of ATMs in obese BLT-1-deficient mice.56 In addition, knockout of 
BLT-1 prevents increases in proinflammatory M1 ATMs, but not M2 responses 
under obesity-induced stress, which ultimately attenuates the inflammatory 
status in white fat tissue of obese BLT-deficient mice.56 
Macrophage polarization 
Adipose tissue macrophages exert profound impacts on homeostasis and 
functions of white adipose tissues through their polarization. The activation 
pattern of ATMs covers a full spectrum of activation stages between well-defined 
classical (M1) and alternative (M2) activation statuses in response to distinct 
microenvironmental cues.57 In response to T helper type 1 (Th1) cytokines, 
lipopolysaccharide (LPS) or free fatty acids, M1 macrophages display classical 
proinflammatory responses depending on TLRs and activation of NFκB/JNK 
signaling pathways.58,59 This cell signaling cascade leads to the release of a set 
of proinflammatory cytokines, such as TNFα and IL1β, which directly impair the 
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 insulin signaling pathway and activate the inflammatory responses of adipocytes 
through paracrine mechanisms.13,60 Recently, an epigenetic landscape at 
cytokine encoding gene loci for these proinflammatory cytokines was 
established during M1 activation.57 Activation of TLR releases epigenetic 
"brakes" such as B-cell CLL/lymphoma 6 (BCL6) from gene loci and concomitant 
induction or activation of demethylases, and removal of inhibitory histone marks 
H3K27me3 and H3K9me3.61-63 In addition, the ATP-dependent complex BAF 
(also known as SWI/SNF) is required for remodeling nucleosomes to facilitate 
recruitment of signaling transcription factor NFκB, and to increase activation 
histone marks such as H3K4me3, and activation of Pol II, ultimately inducing 
expression of proinflammaotry cytokines.64,65 In contrast, the response to Th2 
cytokines such as IL4 and IL13 by M2 macrophages leads to production of anti-
inflammatory cytokines such as IL10 through the recruitment of PPARγ or other 
transcription factors.66,67 In addition, activation of PPARγ-dependent cell 
signaling leads to suppression of the inflammatory phenotype through blocking 
activation of NFκB signaling pathways. Activated PPARγ also induces 
expression of M2 responses-related genes which involve fatty acid metabolism 
and mitochondrial activities.68-70 The IL4-induced activation of STATs promotes 
expression of the histone demethylase JMJD3 that directly binds M2 genes such 
as arginase 1.71 Conversely, histone deacetylase 3 (HDAC3) acts as a "brake" 
repressing IL4-induced M2 responses by deacetylating putative enhancers of 
13 
 
 M2 genes.72-74 Thus, histone methylation and acetylation are essential for the 
expression of M2 activation-associated genes. 
For animals in the lean state, ATMs are preferentially activated as M2 
phenotypes and express genes such as IL10 and arginase 1, which promote 
tissue repair and angiogenesis.52 In the context of obesity, ATMs primarily 
exhibit proinflammatory M1 phenotype in VATs in response to the 
proinflammatory cytokines and chemoattractants.52,75 Lumeng et al. 
demonstrated that resident macrophages in adipose tissue of lean animals 
undergo M2 activation while most macrophages infiltrating into VATs exhibit M1 
phenotypes during the course of animals becoming obese.52 In addition, the 
infiltrated M1 macrophages preferentially locate around the dying adipocytes 
that form “crown-like structures”, and M2 ATMs reside in interstitial spaces 
between adipocytes.52,75 The proinflammatory cytokines secreted by M1 ATMs 
act in an autocrine or paracrine manner to enhance the inflammatory status of 
macrophages and adipocytes in visceral fat tissues of obese individuals.60,75,76 In 
contrast, in a conditional cell ablation system mediated by diphtheria toxin 
receptor to deplete CD11c+ cells, there is a significant decrease in accumulation 
of M1 ATMs in VATs which is accompanied by a decrease in inflammatory 
responses in adipose tissues and eventually improved insulin sensitivity of 
obese mice.77 Given the critical roles of NFκB/JNK in triggering the inflammatory 
responses in ATMs, knockout of IKKβ or JNK suppresses M1 polarization which 
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 is sufficient to attenuate the inflammatory status of white adipose tissue under 
obesity-induced stress.13,78,79 
Besides visceral fat tissues, macrophage polarization has critical roles in 
the development of inflammation in other key metabolic tissues such as liver and 
skeletal muscle.80 Similar to adipose tissue, liver also has resident macrophages, 
termed Kupffer cells, which display a non-inflammatory phenotype and play 
critical roles in maintaining homeostasis of the liver.81-83 Under obesity-induce 
stress, there is a remarkable increase in the recruitment of CCR2+ 
macrophages into liver in response to increases in the chemokine CCL2, and 
these infiltrated macrophages primarily exhibit proinflammatory M1 activation 
that promotes the inflammatory status in liver.84 The transplantation of CCR2-
deficient bone marrow cells into WT mice results in less accumulation of 
macrophages in liver compared to mice that received CCR2+ bone marrow cells 
after being fed a HFD which demonstrated that recruitment of macrophages into 
liver is dependent on CCR2 expression.84 Furthermore, the recruited 
macrophages promote accumulation of hepatic triglycerides due to the up-
regulation of expression of genes required for fatty acid synthesis and 
triglyceride esterification in the context of obesity.84 In the skeletal muscle, some 
studies suggest that macrophage infiltration occurs in the small intermuscular 
adipose depots and that most of these cells exhibit a proinflammatory phenotype 
which impairs insulin signaling in skeletal muscle cells and their uptake of 
glucose.85,86 However, Bruun et al. and Tam et al. reported that skeletal muscle 
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 has no significant increase in macrophage recruitment.87,88 Nevertheless, 
increases in proinflammatory cytokines impair activation of the insulin signaling 
pathway in skeletal muscle.59,85-88  
Regulation of adipose tissue macrophage polarization  
Given the significant contribution of ATM polarization to inflammatory 
responses in white adipose tissue, it is critical to understand the networks 
governed by various transcription factors and epigenetic regulators in controlling 
the activation of ATMs. For example, TLR4-signaling induces expression of 
interferon regulatory factor 4 (IRF4) which exerts inhibitory functions for 
activation of proinflammatory M1 ATMs.89 This is critical to maintain a balance in 
the activation status of ATMs in response to various stimuli in the 
microenvironment. In contrast, loss of IRF4 exacerbates M1 responses of ATMs 
to feeding a HFD, which ultimately promotes insulin resistance.90 The IL4-
activated signaling also induces expression of IRF4 required for expression of a 
set of M2 response-associated genes.71 The histone demethylase Jumonji 
domain-containing protein 3 (JMJD3) removes the inactivatory H3K27me3 
marks at the Irf4 locus and facilitates expression of this transcription factor in 
response to IL4 stimulation.71 Other transcription factors, kruppel-like factor 4 
and 6 (KLF4 and KLF6), members of the zinc finger family, also have profound 
impacts on macrophage polarization.91,92 Upon stimulation with Th2 cytokines, 
such as IL4 or IL13, activation of signal transducer and activator of transcription 
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 6 (STAT6) in macrophages induces expression of KLF4 that is critical for M2 
responses.92 Ectopic expression of KLF4 increases the abundance of PPARγ 
that is accompanied by increased expression of M2 activation-associated genes 
such as arginase 1, mannose receptor (Mrc1), resistin-like α (Retnla), and 
chitinase 3-like 3 (Chi3l3).92 The expression of KLF4 is suppressed in M1 
macrophages upon LPS stimulation, whereas overexpression of KLF4 impairs 
the M1 activation phenotypes, due to its suppression of activities of NFκB by 
attenuating the recruitment of the coactivators p300 and p300/CBP-associated 
factor (PCAF).92 In contrast, KLF4 deficiency enhances NFκB transcriptional 
activity by increasing recruitment of these cofactors.92 Thus, KLF4 is critical for 
suppressing inflammatory responses in macrophages. In the context of obesity, 
there is a significant decrease in the abundance of KLF4 in the stromal vascular 
fraction of VATs in obese individuals, suggesting that the suppression of KLF4 
expression facilitates activation of M1 ATMs.92 In contrast to the roles of KLF4 in 
macrophage polarization, KLF6 promotes an M1 phenotype and suppresses M2 
responses. The expression of KLF6 is induced by stimulation of ATM with IFNγ 
or LPS, but suppressed in response to IL4 and IL13. KLF6 promotes expression 
of M1 activation-associated genes including TNFα, IL1β, COX2, and MIP-1α in 
macrophages, whereas macrophages without KLF6 show attenuated expression 
of these genes.91 KLF6 also has suppressive effects on the M2 phenotype 
induced by IL4, as evidenced by suppression of M2 activation-related genes 
such as arginase 1 and PPARγ in macrophages with overexpression of KLF6.91 
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 Further studies showed that activation of KLF6 enhances the recruitment of the 
NFκB co-activator p300 to the promoter of genes encoding proinflammatory 
cytokines in macrophages upon LPS stimulation.91 KLF6 also acts as a 
repressor of M2 responses by suppressing actions of PPARγ.91 Thus, the 
activation-specific expression of KLF6 plays critical roles in macrophage 
polarization. 
In addition to transcriptional networks, microRNAs (miRNAs) exert an 
additional layer of regulation to control macrophage polarization (Figure 1.3). 
Similar to the expression pattern of key transcription factors during macrophage 
polarization, the myeloid-specific miRNAs are differentially expressed in 
response to distinct stimuli and exert profound impacts on the macrophage 
activation processes. Our recent study demonstrated that miR-223 is a critical 
regulator of ATMs polarization.93 IL4-induced cell signaling dramatically 
increases expression of miR-223 in macrophages; however, its expression is not 
significantly changed in response to stimulation with LPS. The high abundance 
of miR-223 in macrophages favors M2 responses, whereas a deficiency in miR-
223 decreases expression of PPARγ and arginase 1 in IL4-induced M2 
macrophages. In addition, macrophages lacking miR-223 are hypersensitive to 
LPS stimulation, as evidenced by the improvement in expression of 
costimulatory markers CD69 and proinflammatory cytokine TNFα. Furthermore, 
the regulatory functions of miR-223 in M1 macrophages involve its negative 
control of expression of a pro-diabetic gene, Pknox1. In the context of obesity, 
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 miR-223-deficient ATMs preferentially exhibit proinflammatory M1 responses 
and a less anti-inflammatory phenotype than WT ATMs. Bone marrow 
transplantation of miR-223KO ATMs increases the inflammatory status in 
visceral fat depots and subsequent insulin resistance in obese recipient mice fed 
a HFD which suggests that miR-223-regulated macrophage polarization has 
significant effects on adipose tissue functions. Another microRNA, let-7c, has 
similar expression patterns and functions as miR-223 in macrophage 
polarization.94 Ectopic expression of let-7c in LPS-induced M1 macrophages 
diminishes the inflammatory responses including the expression of 
proinflammatory cytokines IL12 and surface marker major histocompatibility 
complex class II (MHC-II). In addition, the LPS-stimulated macrophages show a 
phenotypic switch from M1 to M2 after overexpression of let-7c. Conversely, 
knockdown of let-7c in IL4-induced macrophages results in transition from an M2 
to an M1 phenotype and a reduction in M2 responses, suggesting a critical role 
of let-7c in maintaining M2 responses. Further, the mechanism by which let-7c 
regulates macrophage polarization is related to its suppression of expression of 
target gene CCAAT/enhancer binding protein δ (C/EBPδ) that is a critical 
regulator of inflammatory responses of macrophages.  
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Figure 1.3 microRNA regulation of macrophage polarization in adipose 
tissue. microRNAs exert profound impacts on the differentiation or polarization 
of macrophages. For example, microRNAs such as miR-17-5p, miR-20a, and 
miR-106a repress the differentiation from monocyte to macrophage. miR-223 
and let-7c favors M2 macrophage activation, while miR-125b is a positive 
regulator for the M1 responses.  
 
In contrast to the suppressive effects of miR-223 and let-7c on M1 
activation, miR-125b is a positive regulator of M1 macrophage activation.95 
Macrophages have increased expression of miR-125b upon IFNγ stimulation, 
accompanied by increased expression of costimulatory markers CD69, CD80, 
and CD86. In addition, overexpression of miR-125b further enhances expression 
of these surface markers of macrophages in response to IFNγ stimulation. 
Furthermore, transcription factor IRF4, a negative regulator of M1 activation, is 
the target gene of miR-125b in regulating macrophage activation. Therefore, it is 
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 critical to understand the regulatory networks governed by transcription factors 
or/and miRNAs in controlling the polarization of ATMs. 
Other innate immune cells in adipose tissue 
Emerging evidence has shown that macrophages are not the only 
immune cells contributing to the development of tissue inflammation in the 
context of obesity (Figure 1.4). Neutrophil recruitment from blood to the inflamed 
tissue is a hallmark of early innate immune responses to the secreted 
chemoattractants LTB4 and IL8.96 Elgazar-Carmon et al. reported a significant 
increase in infiltration of neutrophils into VATs 3 days after initiating HFD feeding; 
however, the population of visceral fat tissue neutrophils did not change after 7-
days of feeding a HFD.97 Talukdar et al. found that recruited neutrophils exert 
profound effects on insulin signaling in white adipose tissue and liver through 
secreting pathogenic neutrophil elastase.98 The production of neutrophil elastase 
increases during the course of obesity. Deletion of neutrophil elastase promotes 
insulin sensitivity of liver, as evidenced by the enhanced ability of insulin to 
inhibit hepatic glucose production and reduce concentrations of free fatty acids 
in blood compared to WT mice. In addition, there is an increase in insulin-
stimulated phosphorylation of Akt in white fat depots after depletion of neutrophil 
elastase. Further, neutrophil elastase exhibits suppressive effects on insulin 
action in hepatocytes and adipocytes through degradation of IRS-1, and 
increased TLR4-mediated signaling and macrophage recruitment, which 
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 contributes to the development of inflammation and insulin resistance. A recent 
study reveals that production of the endogenous inhibitor of neutrophil elastase, 
serine protease inhibitor α1-antitrypsin (A1AT), is significantly reduced in livers 
under the stress of obesity due to obesity-induced leptin resistance.99 The 
imbalance between neutrophil elastase and A1AT leads to tissue inflammation 
and insulin resistance in the context of obesity. In contrast, overexpression of 
A1AT or administration of a neutrophil elastase inhibitor can protect individuals 
from obesity-associated metabolic abnormalities. Taken together, neutrophils 
are key regulators of tissue function in the context of obesity. 
Resident eosinophils in white adipose tissue are the major cells secreting 
IL4 to sustain M2 activation of ATMs.100 Along with M2 ATMs, the proportion of 
eosinophils in adipose tissue is negatively correlated with adiposity in mice due 
to the reduction of innate lymphoid type2 (ILC2) cells that secret IL5 and IL13 to 
recruit eosinophils.101,102 In addition, the ILC2 cells induce production of 
chemokines CCL11 and CCL24 from adipocytes to recruit eosinophils. 
Eosinophil deficient mice have low numbers of M2 macrophages in VATs and 
subsequent insulin sensitivity. Conversely, increases in eosinophils in adipose of 
IL5 transgenic mice induce M2 activation of ATM and protect them from obesity-
induced insulin resistance. These studies provide strong evidence for critical 
roles of eosinophil in maintaining metabolic homeostasis in white fat depots. 
Given the critical roles of ILC2 cells in recruiting eosinophils, loss of ILC2 cells 
leads to a decrease in the population of adipose tissue eosinophil and 
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 subsequent M2 ATM content that eventually compromises insulin sensitivity of 
adipose tissue.101 These characteristics mirror the phenotype of eosinophil-
deficient mice. Thus, eosinophils play a role in the maintenance of M2 
polarization in adipose tissue in obese individuals via secretion of anti-
inflammatory cytokines IL4 and IL13. 
Mast cells are critical regulators of allergic responses and tissue 
homeostasis and remodeling through secreting groups of proinflammatory and 
immunomodulatory molecules such as histamine, cytokines, chemokines, and 
proteases. Given that the development of obesity involves extracellular matrix 
remodeling and angiogenesis, significant increases in the recruitment of mast 
cells into white adipose tissues is accompanied by expansion of adipose tissue 
mass.35,103 Liu et al. demonstrated that mast cells residing in white fat pads 
exhibit important functions with respect to energy expenditure and glucose 
homeostasis in the context of obesity.103 Using a mast cell-deficient mouse 
model, their results suggest that mast cells contribute to obesity-induced 
expansion of adipose tissue mass by stimulating expression of proteases and 
promoting angiogenesis in white adipose tissues. Further, adoptive transfer of 
cytokine-deficient mast cells revealed that IL6 and IFNγ secreted by mast cells 
induce expression of the cysteine protease cathepsin in adipose tissue. In 
addition, pharmacological stabilization of mast cells efficiently protects mice on a 
HFD from obesity-induced metabolic syndrome. Thus, mast cells may link 
inflammation to tissue remodeling in white adipose tissue in obese individuals. 
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 Functions of adipose tissue T cells 
In addition to the innate immune responses, the adoptive immune cells 
such as T lymphocytes located in adipose tissue exert profound impacts on the 
metabolic functions of adipose tissue (Figure 1.4). The resident CD3+ T cells in 
adipose tissue account for about 10% of the stromal vascular fraction in lean 
mice,104 and there are two main groups of CD3+ T cells dependent on their 
phenotypic expression of the surface co-receptor CD4 or CD8. Further, CD4+ T 
cells in adipose tissues can be subcategorized into proinflammatory Th1 and 
Th17 cells and anti-inflammatory regulatory T (Treg) and Th2 cells.  
In the context of obesity, the VATs are also characterized by an increase 
in the accumulation of IFNγ-secreting Th1 cells and a diminished population of 
Th17 cells.104 The tissue-specific lymphocyte accumulation mainly depends on 
the MHC-antigen conjugate. Winer et al. demonstrated that T cells in adipose 
tissue undergo selective pressure in the complementarity determining region 3 
(CDR3) region to generate T cell receptors (TCRs) that recognize specific 
antigens in fat.104 This suggests that the expansion of T cells in VATs is driven in 
an antigen-specific manner in the context of obesity. Interestingly, there is no 
significant change in the accumulation of CD4+ T cells in subcutaneous fat 
depots during the development of obesity.104 This may be due to the great 
polyclonal repertoire of CD4+ T cells residing in subcutaneous adipose 
tissues.104,105 Although the ATMs are antigen-presenting cells,106 some studies 
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 found that T cell expansion in VATs precedes changes in the population of 
ATM.104,107,108 A recent study provides evidence that adipocytes enhance 
activation of the MHC II pathway to facilitate expansion of CD4+ T cells in VATs 
during the early stages of development of obesity.109 After 2 weeks of a HFD, 
expression of the adipokine leptin increases and stimulates production of IFNγ 
by resident CD4+ Th1 cells to induce the expression of MHC II in adipocytes of 
mice.109 In addition, adipocytes of VATs exhibit greater expression of MHC II 
compared to that for subcutaneous fat depots which may account for the lack of 
change in CD4+ T cells in subcutaneous fat.109 Knockout of MHC II in 
adipocytes decreases CD4+ T cells in adipose tissues,109 suggesting critical 
roles for expression of MHC II by adipocytes in controlling proliferation and 
activation of CD4+ T cells. Furthermore, Th1 cells act as positive regulators of 
adipose tissue inflammation through MHC II-mediated IFNγ production and 
activation of M1 ATMs.108,109 In contrast, MHC II-deficient mice show reduced 
accumulation of CD4+ T cells in VATs, accompanied by decreased IFNγ 
production and the proportion of M1 ATMs under the stress of obesity.109,110  
In contrast to the increased expansion of proinflammatory Th1 cells, there 
is a decreased the proportion of adipose tissue resident Treg cells that exert 
anti-inflammatory effects in the context of obesity.104,111 Similar to Th1 cells in 
adipose tissue, Treg cells that reside in VATs have a unique T cell receptor 
repertoire for the recognition of specific antigens compared to Treg cells in the 
lymph nodes.105 In addition, Cipolletta et al. reported that activation of the 
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 PPARγ-dependent signaling pathway is critical for controlling the accumulation 
and phenotype of Treg cells residing in adipose tissues.112 The obesity-induced 
decrease in production of IL4 that can trigger PPARγ action may account for the 
decreased population of Treg cells in adipose tissue in the context of obesity. 
Given its anti-inflammatory function, resident Treg cells in adipose tissue 
attenuate the inflammatory status. Depletion of Treg cells significantly 
exacerbates adipose tissue inflammation and insulin resistance under obesity-
induced stress.111 Conversely, expansion of Treg cells in adipose tissue by 
injection of IL2 and IL2-specific monoclonal antibody prevents obesity-
associated metabolic abnormalities in mice.111 Restoration of Treg cells in VATs 
by CD3-specific antibody promotes insulin sensitivity in obese mice.104 
In addition to CD4+ T cells, CD8+ T cells accumulate in VATs in the 
context of obesity.107 However, there is no significant change in the population of 
CD8+ T cells in subcutaneous fat depots.107 Jiang et al. demonstrated that the 
expression of CD11a, a component of lymphocyte function antigen-1 (LFA-1) 
expressed on T cells, plays a critical role in the accumulation of CD8+ T cells in 
VATs through interaction with intercellular adhesion molecule-1 on 
adipocytes.113 Indeed, the population of CD11ahighCD8+ T cells increases in 
VATs during the course of development of obesity, whereas obese mice 
depleted of CD11a have fewer CD8+ T cells resident in VATs compared to 
obese WT mice.113 Nishimura et al. suggested that the infiltration of CD8+ T 
cells into VATs occurs within 2 weeks after mice are placed on a HFD, and the 
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 number of CD8+ T cells reaches a peak after mice are fed a HFD for 15-
weeks.107 In addition, cytokines such as IL2, IL12, and IL18 secreted by cells in 
adipose tissue of obese mice promote proliferation and activation of CD8+ T 
cells.107 Furthermore, CD8+ T cells are required for the infiltration of 
proinflammatory macrophages into adipose tissues obese individuals in 
response to the release of chemokine CCL2 during the early stages of obesity 
which is critical to the initiation of the inflammatory cascade in the adipose tissue 
depots.107 Depletion of CD8+ T cells prevents increased recruitment of 
macrophages into adipose tissues and proinflammatory responses of ATMs in 
response to feeding a HFD and this is accompanied by attenuation of the 
inflammatory status of adipose tissues.107 
Given the significant impacts of T cells on the functions of VATs, it is 
critical to understand the regulatory mechanism for the activation of T cells. The 
transcriptional controls are essential to regulate immunological functions of T 
cells in response to various cues in the microenvironment. As discussed earlier, 
Treg cells in adipose tissue exhibit a distinct phenotype such as a T cell receptor 
repertoire that differs from that of their counterparts in spleen and lymph 
nodes.105 Cipolletta et al. provided evidence that PPARγ has specific 
transcriptional control of gene expression patterns in Treg cells that are resident 
in VATs compared to the PPARγ functions in Treg cells in lymph nodes.112 Gene 
expression profiling revealed that PPARγ actions promote expression of genes 
related to leukocyte migration and activation in resident Treg cells in VAT, but 
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 not Treg cells in lymph nodes. Furthermore, enhanced PPARγ activation 
increases expression of chemokine receptor CCR2 and a key transcription factor 
forkhead box P3 (FOXP3), that is accompanied by increased accumulation and 
activation of Treg cells in VATs under the stress of obesity.112 The activated 
Treg cells exert their immunoregulatory functions primarily through 
transcriptional networks controlling production of the anti-inflammatory cytokine 
IL10. For example, in response to the inflammatory conditions, the production of 
IL10 from Treg cells requires activation of transcription factor PR domain 
containing 1, with zinc finger (ZNF) domain (PRDM1, also known as BLIMP1) 
that is induced by the IRF4-dependent cell signaling pathway.114 In addition, 
PRDM1 acts via a negative feedback loop to limit accumulation of Treg cells in 
tissues by suppressing expression of pro-survival factor BCL2 and chemokine 
receptor CCR6.114 
Recent studies reveal that miRNA-mediated gene regulation represents a 
fundamental layer of post-transcriptional control of differentiation and activation 
of T cells. For example, miR-181a has profound functions in regulating TCR 
signaling that is critical for T cell development and homeostasis.115 Repression 
of miR-181a using specific antisense oligonucleotides dampens TCR sensitivity 
and impairs positive and negative selection of T cells in the thymus, whereas 
ectopic expression of miR-181a in mature T cells enhances their sensitivity to 
peptide antigens.115 miR-181a can directly suppress the expression of 
phosphatases that decrease TCR signals, including protein tyrosine 
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 phosphatase type 11 (Ptpn11), Ptpn22, dual-specificity protein phosphatase 5 
(Dusp5), and Dusp6, thereby lowering the TCR engagement threshold for 
cellular responses.115 Another miRNA, miR-146a, is induced following TCR 
engagement and serves as an important feedback regulator of NFκB signaling 
that is a downstream component of the cascade for TCR signaling.116 Further 
study revealed that miR-146a prevents the hyper-responsive inflammatory 
response in activated T cells through targeting NFκB signal transducers TNF 
receptor-associated factor 6 (Traf6) and IL1 receptor-associated kinase 1 
(Irak1).117 Zhao et al. observed that miR-146a-deficient mice have spontaneous 
myeloproliferation and myeloid cell tumorigenesis due to loss of the miR-146a-
dependent feedback loop.118 However, the regulatory networks in controlling 
differentiation and activation of resident T cells in adipose tissue to various 
stimuli have not been elucidated. 
Function of adipose tissue B cells 
Given the essential role of B cells in adoptive immune responses, adipose 
tissue resident B cells exert profound impacts on the function of adipose tissues 
in response to the alterations in cues in the microenvironment. B cells are 
originally generated in bone marrow, and mature B cells are released from 
spleen into the bloodstream. The chemokine chemokine (C-X-C motif) ligand 13 
(CXCL13) is one of the critical mediators of B cell migration into tissues where 
they encounter antigens and undergo activation.119 Interestingly, the recruitment 
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 of circulating B cells into VATs occurs shortly after the initiation of feeding a HFD, 
and the population of B cells reaches a peak 3 to 4 weeks later to become one 
of the major immune cells populations in white fat depots (Figure 1.4).110,120 
Winner et al. suggested that activation of adipose tissue B cells increased 
immunoglobulin class switching to IgM+IgD- or IgG+ phenotypes, especially to 
pro-inflammatory IgG2c under the stress of obesity.110 This increase in 
pathogenic IgG antibodies directly interrupts insulin signaling in key metabolic 
tissues such as liver and skeletal muscle through interactions with antigenic 
targets that are associated with the endoplasmic reticulum stress.110 In addition, 
adipose tissue B cells promote MHC-dependent activation of CD4+ and CD8+ T 
cells in adipose tissue niches which contributes to increased production of pro-
inflammatory cytokines such as IFNγ and subsequent induction of activation of 
M1 macrophages.110 Mice without mature B cells have reduced activation of 
proinflammatory T cells and macrophages in VATs and improved insulin 
sensitivity under the stress of obesity as compared to obese WT controls.110 In 
contrast, the adoptive transfer of IgG antibodies isolated from HFD-fed WT mice 
exacerbates insulin resistance of HFD-fed B-cell-deficient mice in a Fc-
dependent manner, suggesting that IgG antibodies are mediators of B cell 
function in regulating insulin sensitivity in the context of obesity.110 In contrast to 
the pathogenic IgG antibodies, a recent study suggests that B cells in adipose 
tissue produce and secrete more proinflammatory cytokines such as IFNγ and 
IL6, but less anti-inflammatory IL10 in obese compared to lean control mice.121 
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 This obesity-induced alteration in cytokine expression patterns by B cells in 
adipose tissue increases the Th1/Th17 to Treg cell ratio in white fat depots 
leading to adipose tissue inflammation and insulin resistance.121 However, 
obese mice without mature B cells accumulate more Treg cells compared to the 
WT mice on a HFD, indicating the critical role of B cells in regulating T cell 
homeostasis in adipose tissue in the context of obesity.119 However, 
mechanisms regulating expression of cytokines by B cells in adipose tissue and 
their impact on the adipose tissue T cell homeostasis have not been elucidated. 
In addition, like T cells, B cells are not homogeneous, and consist of distinct 
subsets including B1 and B2 cells, which differ in their location and function. B1 
cells are enriched in mucosal tissues and pleural/peritoneal cavities, and these 
cells preferentially undergo T-cell independent activation when encountering 
antigens. B2 cells accumulate in secondary lymphoid organs such as lymph 
nodes and spleen, and mainly respond to T-dependent antigens responsible for 
adoptive humoral immunity. In the context of obesity, both B1 and B2 cells are 
recruited into VATs, but their roles in this niche have not been elucidated.  
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 Besides B1 and B2 cells, there is a group of IL10/transforming growth 
factor β (TGFβ)-secreting regulatory B (Breg) cells that reside in adipose tissue to 
prevent excessive and pathological inflammatory responses. Nishimura et al. 
reported that the adipose tissue Breg cells are characterized by their constitutive 
production of IL10 through activation of PI3K/Akt signaling in response to the 
release of fatty acids from adipocytes.122 However, the spleen or bone marrow 
Breg cells do not express IL10 under basal physiological conditions. The C-X-C 
chemokine receptor type 4 (CXCR4) ligand CXCL12 released from adipose 
tissue contributes to the recruitment of IL10-producing regulatory B cells into 
adipose tissues.122 In addition, a recent study by Wu et al. suggests that the 
spleen serves as a source of Breg for the recruitment of these cells into the 
peritoneal cavity and VATs.123 These IL10-secreting adipose tissue Breg cells 
have suppressive effects on activation of proinflammatory CD8+ T cells and 
macrophages, as evidenced by an enhanced population of these cells in 
adipose tissues after mutation of of IL10 expression in Breg cells.122,123 In the 
context of obesity, the proportion of adipose tissue Breg cells is diminished due to 
decreased production of CXCL12 by adipocytes of obese individuals and this 
eventually contributes to exacerbation of inflammation and insulin resistance.122 
IL10 can also promote the viability of adipose tissue Breg cells, whereas the 
reduction of IL10 in the context of obesity accounts for the decreased proportion 
of Breg cells residing in adipose tissues. 
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 The activation of B cells requires antigen-induced B cell receptor (BCR) 
signaling and signaling via cytokine receptors and co-stimulatory receptors. In 
response to distinct cues in the microenvironment, regulation of these complex 
processes during B cell activation involves regulatory networks governed by 
various mediators that include microRNAs. The microRNAs have critical roles in 
orchestrating the regulatory networks that activate B cells. For example, Mraz et 
al. recently reported that miR-150 activates B cell receptors by negatively 
controlling expression of GRB2-associated binding protein 1 (GAB1) and FOXP1. 
An abnormally high abundance of miR-150 in chronic lymphocytic leukemia 
significantly represses expression of GAB1 and FOXP1 and subsequently 
impairs the activity of B cell receptor signaling.124 Another extensively studied 
micoRNA in mature B cell is miR-155 which has significant effects on immune 
responses of B cells.125 Mature B cells without miR-155 expression produced 
less IgG1 and cytokines such as TNFα. Further, miR-155 negatively controls 
expression of PU.1 that is a critical transcription factor downstream of the BCR 
signaling pathway in mature B cells.125 However, the regulatory mechanisms for 
activation of B cells in adipose tissue has not been elucidated. 
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Figure 1.4 The interplay between immune cells and adipocytes in adipose 
tissue. In adipose tissue of lean mice, interleukin 5 (IL5) and IL13-producing 
inate lymphoid (ILC2) cells promote the maturation and recruitment of 
eosinophils that are the major source of IL4 in adipose tissue. Activated Treg 
cells respond to secrete anti-inflammatory IL10. Both IL4 and IL10 maintain the 
alternative M2 phenotype of adipose tissue macrophages (ATMs). In addition, 
adiponectin released from adipocytes contributes to the maintenance of the M2 
phenotype of ATMs. In adipose tissue of obese individuals, adipocytes undergo 
cellular stress and secrete proinflammatory cytokines and chemokines which 
significantly elevate the population of proinflammatory M1 ATMs. Neutrophils 
also infiltrate into adipose tissues during the development of obesity and 
promote inflammation and insulin resistance by secreting tumor necrosis factor 
alpha (TNFα) and elastase. Mast cells can produce IL6 and interferon gamma 
(IFNγ) to promote activation of M1 ATMs. Macrophages and adipocytes activate 
Th1 cells in a major histocompatibility complex (MHC)-antigen manner. Adipose 
tissue resident B cells are also able to present antigens on MHC molecules to 
either CD8+ T cells or Th1 cells. In addition, B cells secrete pathogenic antibody 
IgG2c and proinflammatory cytokines. Thus, the interplay among these immune 
cells eventually contributes to insulin resistance.  
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 PPARγ agonists as anti-inflammatory therapies for insulin resistance 
Given the critical roles of resident immune cells in tissue with respect to 
inflammation and insulin resistance in the context of obesity, therapeutic 
strategies to repress recruitment and activation of proinflammatory immune cells 
have potential importance.  
PPARγ signaling exerts profound effects that regulate activation of 
immune cells including M2 macrophages and Treg cells.66,112 Consistent with 
this notion, the antidiabetic thiazolidinediones (TZDs) including rosiglitazone and 
pioglitazone are PPARγ ligands that promote activation of anti-inflammatory 
immune cells that reside in adipose tissues.66,112 For example, the TZDs exhibit 
robust anti-inflammatory effects and promote M2 responses in macrophages 
which contributes to the attenuated inflammation and insulin resistance in 
adipose tissue. Treatment with TZDs also enhances eosinophil numbers and 
activation of anti-inflammatory Treg cells in adipose tissue of obese 
individuals.112,126,127 In addition, PPARγ acts as insulin sensitizer by triggering 
the PPARγ-dependent transcriptional programs in various metabolic cell 
types.126 Indeed, these drugs improve insulin sensitivity in key metabolic tissues 
including liver, adipocytes, and skeletal muscle.  
Interferon tau: An anti-inflammatory cytokine 
Interferon tau (IFNT) is secreted by mononuclear trophectoderm cells of 
ruminant conceptuses and was originally determined to be the pregnancy 
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 recognition signal for establishment of pregnancy in ruminants such as sheep 
and cows.128 IFNT is a member of type I interferon family, and this cytokine 
shares high amino acid sequence similarities with other type I interferons such 
as IFN alpha (IFNA) and IFN omega (IFNW).129 IFNT also possesses antiviral, 
anti-proliferative, and immunomodulatory activities, with very low cytotoxicity 
even at high dosages.129  
Previous studies demonstrated the potential anti-inflammatory function of 
IFNT in various diseases models. For example, Soos et al. report that IFNT 
significantly prevented development of experimental allergic encephalomyelitis 
(EAE) through suppressing the expansion of proinflammatory CD4+T cells and 
production of TNFα following superantigen staphylococcal enterotoxin B (SEB) 
stimulation.130 Results of a further study using the myelin basic protein (MBP)-
specific TCR-transgenic mouse model suggests that IFNT promotes the 
production of IL10 and Th2 cytokines such as IL4 and IL5, but diminishes the 
secretion of Th1 cytokine IFNγ that attenuates EAE.131 In addition, Chaouat et al. 
observe that in vivo injection of recombinant ovine IFNT significantly enhances 
the production of IL10 and IL4 that is sufficient to prevent fetal resorption in mice 
having a CBA x DBA/2 placental genotype.132 Similarly, in pregnant sheep, IFNT 
limits the immune responses to the conceptus by suppressing the expression of 
MHC I and β2 micoglobulin in uterine luminal and superficial glandular 
epithelia.133 Using the non-obese diabetic mouse model, oral, intraperitoneal, or 
subcutaneous supplementation of IFNT delays the development of diabetes by 
36 
 
 repressing pancreatic islet inflammation and increasing the number of splenic 
Treg cells.134 Taken together, IFNT is a potential therapeutic treatment of 
obesity-induced tissue inflammation. 
miRNAs and their therapeutic application in obesity 
miRNAs are a group of highly conserved small noncoding RNAs (~22 
nucleotides in length) that are produced by two RNase III proteins, Drosha and 
Dicer.135 miRNAs function primarily through RNA silencing which is initiated by 
base pairing with their target mRNAs.136 In this context, argonaute (AGO) 
proteins serve as effectors by recruiting factors that induce translational 
repression, mRNA deadenylation and mRNA decay. miRNA-binding sites are 
usually located in the 3’ untranslated region (UTR) of their target genes. The 
domain at the 5’ end of miRNAs that spans from nucleotide position 2 to 7 is 
crucial for target recognition and has been termed the ‘miRNA seed’. The 
downstream nucleotides of miRNA (particularly nucleotide 8 and less importantly 
nucleotides 13-16) also contribute to base pairing with the target mRNAs. It is 
known that over 60% of human protein-coding genes contain at least one 
conserved miRNA-conserved miRNA-binding site and, considering that 
numerous non-conserved sites also exist, most protein-coding genes may be 
under the control of miRNAs.  
Given the extensive regulation of miRNAs on protein-coding genes, it is 
not surprising that miRNAs also exert profound impacts on genetic networks and 
37 
 
 subsequent physiological processes. Dysregulated expression of miRNAs in 
human and animal models are associated with various diseases and their 
progression, including obesity-associated metabolic syndrome that includes 
cardiovascular diseases.137 However, how miRNAs regulate functions of tissue-
resident immune cells such as adipose tissue resident B cells in the context of 
obesity is not well understood.  
The recent discovery of extracellular miRNAs opens a new window to the 
understanding the functional mechanisms of this small non-coding RNA family. 
Interestingly, the expression patterns of extracellular miRNAs are correlated with 
various diseases, including type 2 diabetes and atherosclerosis, suggesting their 
potential roles as biomarkers for diagnosis of those diseases. Concentrations of  
miR-125a-5p, miR-126-3p, miR-221-3p and miR-222-3p in serum are reduced in 
patients with atherosclerosis compared to healthy subjects.138 Extracellular 
miRNAs may present in different formats, including exosomal particles, 
microvesicles and argonaute-bound molecules.137 However, major questions 
regarding their secretion and remote tissue targeting remain unanswered. For 
example, extracellular miRNAs can be passively released by damaged tissues 
and cells or be actively secreted by cells, acting as cell-cell communication 
factors. Further endeavors are necessary to address these questions so that 
translational therapeutic strategies can be developed and put into practice. 
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 CHAPTER II 
MIR-150 REGULATES INSULIN SENSITIVITY THROUGH 
MODULATION OF B CELL FUNCTION: A NOVEL PARADIGM 
FOR THE DEVELOPMENT OF INSULIN RESISTANCE 
Resident B cells in adipose tissue account for 20% of the stromal cell 
population. However, their function and mechanisms of action in the adipose 
tissue niche are poorly elucidated. In this study, I report that miR-150, a crucial 
regulator for B cell formation and activation, is a potent modulator for obesity 
associated adipose tissue function by controlling activation of B cells and their 
cell-cell interactions with other immune cells. Mice with miR-150 deficiency 
display exacerbated obesity-associated tissue inflammation and systemic insulin 
resistance. This phenotype is recapitulated by the adoptive transplantation of 
isolated miR-150KO-B cells from obese mice into mice lacking B lineage (Bnull), 
but not isolated immunoglobulin. Further, miR-150 deficient B cells exert potent 
stimulatory effects on both T cells and macrophages, ultimately leading to 
increases in inflammation and insulin resistance in adipose tissue. Several target 
genes of miR-150 have been identified and knockdown of these genes 
individually or together alleviated B cell actions upon stimulation by altering 
important pathways downstream of the B cell receptor complex. My results 
demonstrate a critical role for B cell function in adipose tissue, and that miR-150 
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 and its regulatory molecular network are crucial regulators of both metabolic and 
immune homeostasis in the adipose tissue niche. 
Introduction 
Immune cells in adipose tissue orchestrate homeostasis of immunological 
and metabolic functions in adipose tissue.5,80,139-141 Significantly increased 
numbers of immune cells are crucial for the pathogenesis of obesity-induced 
chronic low grade inflammation, systemic insulin resistance, and subsequent 
high risk for cardiovascular diseases, type 2 diabetes, and metabolic 
syndrome.44,107,142-145 Among various immune cell lineages that infiltrate into 
adipose tissue of obese individuals, B cells become one of the major immune 
cells compared to their profiles in lean individuals, in both absolute numbers and 
relative proportion to visceral stromal cells.110,121,122 However, the function of 
adipose tissue resident B cells (ATBs) and their mechanisms of action have not 
been clearly elucidated. 
In mouse models of obesity, the accumulation of B cells in visceral 
adipose tissues (VATs) reaches a peak 3 to 4 weeks after initiation of feeding a 
high-fat diet (HFD) and VATs become one of the major immune cell 
compartments in the adipose tissue niche.110 Results of recent studies suggest 
that B cells exert profound effects on adipose tissue homeostasis by influencing 
antibody production and cell-cell interactions with other immune cells.110,121 
Importantly, B cells are heterogeneous, consisting of two distinct major subtypes, 
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 B1 and B2, which are unique in their immune responses and interactions with 
other cells. For example, B1 cells, a major subtype of peritoneal B cells, exhibit 
more rapid immunological responses than B2 cells, but with a less-diverse and 
more poly-reactive antibody repertoire.146-154 Although the populations of both B1 
and B2 cells increase in adipose tissue of obese individuals,110 the contribution 
of these B cell subsets to the pathogenesis of obesity-associated metabolic 
disorders remains poorly understood. 
Previous studies, including ours, have demonstrated that miR-150 is a 
crucial regulator for B cell formation.155,156 Ectopic expression of miR-150 in 
hematopoietic stem cells specifically blocks B cell formation at the early 
progenitor stages;155 whereas loss of miR-150 does not have a major impact on 
hematopoiesis except for enhancing the B1a cell sub-population relative to 
B2.156 While accounting for less than 2% of cell types in blood and other major 
immune organs, B1a cells are a major B cell subtype in adipose tissue, 
composing 15% of the B cells.156,157 Therefore, I hypothesize that miR-150 
regulates ATB cell activation and the communication between B cells and other 
immune cells and adipocytes. 
In this study, we probed the function of ATB cells and their functional 
mechanisms of action using a transgenic mouse model, miR-150KO mice, along 
with adoptive transplantation assays. There is a specific increase in B1a cells in 
response to deletion of miR-150, whereas other cells in other hematopoietic cell 
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 lineages are not affected. Using this unique miR-150 null mouse model we 
sought to understand the impact of B cells, specifically B1a cells, in regulating 
adipose tissue function in response to the stress of obesity, in particular, 
resident immune cell functions and cell-cell crosstalk in adipose tissue. 
Furthermore, we identified two new miR-150 target genes, Elk1 and Etf1 in this 
context and demonstrated that Elk1, Etf1, and a known target Myb are important 
mediators for miR-150 regulation of B cell activation. Thus, results of this study 
provides evidence to support a novel paradigm of microRNA regulation of ATB 
cell functions in obese-induced tissue inflammation and insulin resistance, and 
identifies new target genes for drug development to mitigate obesity-associated 
cardiovascular diseases and metabolic syndrome.  
Materials and Methods 
Animals  
The generation of miR-150-deficient (miR-150KO) and Bnull B6 (lack of 
mature B cells) mice has been described.156,158 Wild-type (WT) C57BL/6J mice 
were used as controls. All mice were maintained on a 12/12-hour light-dark cycle. 
Male mice 5 to 6 weeks of age were fed ad libitum. Mice were fed a HFD (Cat. 
No. D12492, Research Diets, Inc; Table A-1) or a low-fat diet (LFD; Cat. No. 
D12450B, Research Diets, Inc; Table A-2) for 12 weeks. After the feeding 
regimen, mice were subjected to phenotypic characterization and metabolic 
assays, including measurement of metabolic parameters in plasma, insulin and 
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 glucose tolerance tests, and immunohistochemical analysis of tissues. All study 
protocols were reviewed and approved by the Institutional Animal Care and Use 
Committee of Texas A&M University. 
Flow cytometry analysis 
Visceral stromal cells from visceral adipose tissue and splenic cells were 
stained with fluorescence-tagged antibodies (0.125 μg/106 cells) to detect cell 
lineages. B cell subtypes were detected with antibodies against CD19 (Cat. No. 
17-0193-82, eBioscience), CD5 (Cat. No. 11-0051-82, eBioscience) and CD43 
(Cat. No. 12-0431-82, eBioscience); T cells were detected with antibodies 
against cell surface markers CD4 (Cat. No. 11-0041-82, eBioscience) and CD8 
(Cat. No. 17-0081-82, eBioscience); myeloid cells were detected with antibodies 
against cell surface markers F4/80 (Cat. No. 11-4801-82, eBioscience), CD11b 
(Cat. No. 45-0112-82, eBioscience) and Gr-1 (Cat. No. 35-5931-82, 
eBioscience); macrophage subtypes were detected with antibodies against cell 
surface markers F4/80, CD11b, CD206 (Cat. No. 141706, Biolegend), CD11c 
(Cat. No. 12-0114-82, eBioscience). Macrophage activation was measured with 
antibodies against cell surface markers CD80 (Cat. No. 17-0801-82, 
eBioscience), CD69 (Cat. No. 45-0691-82, eBioscience), and CD86 (Cat. No. 
11-0862-82, eBioscience). T cell activation was measured using antibodies 
against cell surface markers CD80, CD86, CD69, IFNγ (Cat. No. 48-7311-82, 
eBioscience), and IL2 (Cat. No. 12-7021-82, eBioscience). B cell activation was 
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 measured using antibodies against cell surface markers CD80, CD86, CD69, 
IgA (Cat. No. 12-4204-82, eBioscience), IgM (Cat. No. 47-5790-82, eBioscience), 
and IgD (Cat. No. 17-5993-82, eBioscience). Data were analyzed using Flowjo 
or Accuri C6 (BD Biosciences) or Kluza (Beckman Coulter) software. 
Immune cell isolation analysis 
The T and B cells were isolated from VATs or spleen of wild type or miR-
150KO mice (HFD or LFD). VATs were first mechanically dissociated and then 
subjected to collagenase II (2 mg/mL; Cat. No. 17101-015, Invitrogen; Table A-3) 
digestion for 30 min at 37oC. After lysing red blood cells (Table A-4), a single cell 
suspension was incubated with biotin-labeled antibodies against cell surface 
markers CD4 (Cat. No. 13-9766-82, eBioscience), CD8 (Cat. No. 13-0081-82, 
eBioscience) for T cells, B220 (Cat. No. 48-0452-82, eBioscience) for B cells or 
F4/80 for macrophages. Magnetic beads conjugated with streptavidin (Cat. No. 
557812, BD Biosciences) were applied for cell isolation. Purity of each cell 
population was validated using flow cytometry before being subjected for further 
analysis (Figure 2.1A and B). Bone marrow-derived macrophages (BMDM) were 
prepared as previously described.160 Macrophage maturation was examined by 
flow cytometry with antibodies against F4/80 and CD11b (Figure 2.1C). 
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Figure 2.1 Immune cell isolation. Purified splenic CD8+ T cells (A) and CD4+ 
T cells (B) and bone marrow-derived macrophages (C) were analyzed by flow 
cytometry with antibodies against cell surface markers CD8, CD4, F4/80 and 
CD11b, respectively. FSC, forward scatter. 
 
 
 
Immune cell activation analysis 
In the B cell activation assay, naïve B cells from spleen were stimulated 
with lipopolysaccharide (LPS, 10 μg/mL) for T-cell independent activation or 
interleukin 4 (IL4, 10 ng/mL)/anti-CD40 (10 μg/mL; Cat. No. 14-0401-85, 
eBioscience) for T-cell dependent activation. The macrophage polarization 
assay was carried out following the protocol described previously.93,159 For 
macrophage polarization analysis, BMDMs were stimulated with LPS (100 
ng/mL) for activation of M1 or IL4 (20 ng/mL) for M2 polarization. T cells were 
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 activated by anti-CD3 (Cat. No. 16-0031-85, eBioscience) and anti-CD28 (Cat. 
No. 16-0281-85, eBioscience) pre-coated on a cell culture plate.  
Activation of immune cells was examined by flow cytometry with 
antibodies against cell surface markers CD69, CD80, and CD86, Bioplex assays 
for cytokine production profiles, and quantitative RT-PCR for gene expression 
analysis. Concentrations of immunoglobulin including IgA (Cat. No. 88-50450-22, 
eBioscience), IgE (Cat. No. 88-50460-22, eBioscience), IgG1 (Cat. No. 88-
50410-22, eBioscience), IgG2a (Cat. No. 88-50420-22, eBioscience), IgG2b 
(Cat. No. 88-50430-22, eBioscience), IgG2c (Cat. No. 88-50670-22, 
eBioscience), and total IgG (Cat. No. 88-50550-22, eBioscience) in plasma or B 
cell culture supernatant were measured using ELISA kits according to the 
manufacturer’s instructions. 
Adoptive transplantation assay 
After 12 weeks on a high fat diet, spleens were collected from HFD WT 
and miR-150KO mice and mechanically dissociated. After lysing red blood cells 
(Table A-4), B220+ B cells from spleen were purified using anti-mouse 
CD45R/B220 (Cat. No. 13-0452-85, eBioscience) conjugated to magnetic 
particles (Cat. No. 557812, BD Biosciences). The purity of B cell was determined 
by flow cytometry with antibodies against cell surface marker B220 (Figure 2.2). 
A total of 1x107 B220+ B cells in 150 μL of PBS were transplanted into each 
HFD Bnull mouse via intraperitoneal (i.p.) injection. HFD Bnull mice without B cell 
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 transfer were controls. Cell engraftment in visceral fats and adjacent organs, as 
well as glucose tolerance were determined 2 weeks after the B cell injection.  
 
Figure 2.2 Isolation of splenic B cells for adoptive transplantation assay. 
B220+ B cells were purified from wild type (WT) or miR-150knockout (miR-
150KO) mice fed a high fat diet using anti-mouse B220 conjugated magnetic 
beads. The results indicate that the about 90% of cells used for adoptive 
transplantation were B220+ cells. FSC, forward scatter.  
miR-150KO WT 
B
22
0 
FSC 
90% 92% 
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 Cell co-culture assay 
The B cells isolated from spleens of WT or miR-150KO B cells were pre-
activated with LPS (10 μg/mL), or IL4 (10 ng/mL)/anti-CD40 (10 μg/mL). After 48 
h activation, pre-activated B cells were mixed with WT CD4+ or CD8+ T cells 
that were pre-activated using anti-CD3 (10 μg/mL) and anti-CD28 (10 μg/mL) 
pre-coated tissue culture plates at a ratio of 10:1. After activation for 96 h, pre-
activated B cells were co-cultured in a trans-well plate with WT M1 (LPS, 100 
ng/mL) or M2 (IL4, 20 ng/mL) BMDMs at a ratio of 1:10. The activation of co-
cultured cells was examined as described in the section titled Immune cell 
activation analysis.  
Isolation and injection of IgG 
Immunoglobulin G (IgG) proteins were isolated from plasma of HFD-WT 
or miR-150KO mice using Dynabeads® Protein G (Cat. No. 10003D, Invitrogen). 
The IgG proteins were validated for their purify by gel electrophoresis (Figure 
2.3). A total of 150 μg of IgG proteins in 150 μL of PBS were transferred into 
each HFD Bnull mouse via i.p. injection on Day 0 and Day 3. HFD Bnull mice 
without IgG protein transfer were controls. A glucose tolerance test was 
performed 1 week after injection of IgG. 
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Figure 2.3 Immunoglobulin (Ig) G purification. IgG proteins were purified from 
plasma of wild type mice (WT) or miR-150knockout (miR-150KO) mice fed a 
high fat diet (HFD). 
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 Luciferase reporter assay 
The luciferase reporter assay was carried out following the protocol 
described previously.93 Briefly, the full 3’-untranslated region (3’-UTR) sequence 
of the predicted target gene or at least the 250-bp flanking region of the 
predicted miR-150 binding site was cloned into the psiCheck2 Vector (Promega) 
downstream of the Renilla luciferase-coding region. The reporter constructs with 
oligonucleotides that mimic miR-150 or negative control oligonucleotides were 
cotransfected into HEK293 cells. At 48 h after co-transfection, the activities of 
Renilla luciferase were measured using the Dual-Glo luciferase reporter system 
(Cat. No. E2920, Promega) and normalized to the internal control firefly 
luciferase activity. Repressive effects of miR-150 on target genes were plotted 
as percentage repression in three biological assays that each contained three 
technical repeats. 
Gene-specific knockdown with shRNAs 
The pLKO.1-CMV-TurboGFPTM vector (Sigma-Aldrich) with inserted 
shRNAs (targeting Myb, Elk1 or Etf1) was co-transfected with compatible 
packaging plasmids into HEK293T cells. The lentiviral supernatants were 
collected 72 h after transfection and used to infect purified splenic B220+ B cells. 
The empty vector was used as the control. 
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 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 
Total RNA was extracted from adipose tissue B cells or BMDMs using the 
Trizol extraction protocol according to the manufacturer’s instructions (Cat. No. 
R2050, Zymo Research). Gene expression analysis was performed using a 
iScript One-Step RT-PCR kit with SYBR Green (Cat. No. 170-8893, Bio-Rad) on 
Bio-Rad CFX384 (Bio-Rad). Data presented correspond to the mean of 2-ΔΔCt 
from at least three independent experiments after being normalized to β-actin.  
Bio-Plex protein expression assay 
The concentrations of IL1β, tumor necrosis factor-α (TNFα), IL6, IL10, 
and chemokine (C-C motif) ligand 2 (CCL2) in plasma were determined using a 
Bio-PlexTM cytokine assay (Cat. No. M60-009RDPD, Bio-Rad). Concentrations of 
insulin in plasma were determined using the Bio-Plex pro mouse diabetes insulin 
set (Cat. No. 171-G7006M, Bio-Rad). The abundance of total (Cat. No. 171-
V60007M, Bio-Rad) and phosphorylated (Cat. No. 171-V50011M, Bio-Rad) c-
Jun N-terminal kinases (JNK) in mature adipocytes were determined using the 
Bio-Plex cell signaling magnetic assays (Bio-Rad). These Bio-Plex assays were 
performed using the Bio-Plex MAGPIXTM multiplex reader (Bio-Rad). Results 
were analyzed using Bio-Plex Data ProTM software (Bio-Rad).  
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 Statistical analyses  
Results are expressed as means ± SEM. Each data point derived from reverse 
transcription PCR assays represents an average of two technical replicates, and 
data were averaged over independently replicated experiments (n = 3-4 
independently collected samples) and analyzed using the Student’s t test. The 
overall group-effect was analyzed for significance using two-way ANOVA and 
Bonferroni post-test for each factor at each individual time. Data analyses were 
performed using Graphpad Prism version 6.0 software. A value of P<0.05 was 
considered statistically significant. 
Results 
miR-150 deficiency exacerbates obesity-Induced systemic insulin 
resistance 
Previous studies, including ours, demonstrated that miR-150 is a critical 
hematopoietic regulator that exerts profound effects on B cell formation.155,156 A 
miR-150 deficiency in mice enhances formation of B1 cells, a subtype of the B 
lineage that accounts for more than 15% of resident B cells in adipose 
tissue.156,157 To evaluate adipose tissue function under the stress of obesity, we 
challenged miR-150KO mice by feeding a HFD for 12 weeks. The miR-150KO 
mice on the HFD (HFD-miR-150KO) displayed no significant differences with 
respect to body weight gain or food intake compared to age-matched HFD wild 
type control mice (HFD-WT; Figure 2.4). However, HFD-miR-150KO mice 
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 exhibited a significant increase in systemic insulin resistance and tissue 
inflammation as evidenced by results from glucose tolerance and insulin 
sensitivity tests (Figure 2.5A and B). The miR-150KO mice fed a LFD did not 
display abnormal concentrations of glucose or insulin in plasma during either the 
fasted or fed states compared to LFD wild type control mice. After 16 weeks on 
a the HFD, miR-150KO mice exhibited significantly higher concentrations of 
glucose and insulin in plasma, suggesting severe obesity-induced 
hyperglycemia and hyperinsulinemia conditions during both the fed and fasted 
states (Figure 2.5C and D). These results suggest that miR-150 is a crucial 
regulator for the development of obesity-induced insulin resistance. 
 
Figure 2.4 Body weight and food intake. During a 12-week feeding period on 
high fat (HFD) or low fat (LFD) diets, the body weight (grams, g) and weekly 
food intake (grams, g) of wild type (WT) and miR150 knockout mice were 
recorded weekly. The results indicate that miR-150 has no significant effects on 
the body weight and food intake of mice. Data are presented as mean ± SEM 
(n=10).  
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Figure 2.5 MicroRNA-150 (miR-150) ablation exacerbates obesity-induced 
systemic insulin resistance compared to that for wild type (WT) mice. A 
and B, Glucose tolerance test and insulin tolerance test after 12 weeks of 
feeding a high fat diet (HFD) or a low fat diet (LFD; n=6-10). The results 
indicated that miR-150 deficient mice showed exacerbated insulin resistance 
under obesity stress. C and D, Concentrations of glucose and insulin in plasma 
of miR-150 deficient (miR-150KO) mice or wild type (WT) mice fed a HFD, or 
fasted for 16 hours were greater than that of HFD-fed WT mice. However, miR-
150 deficiency did not affect the glucose and insulin levels of LFD mice. Data 
are presented as mean ± SEM. *P<0.05. 
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 miR-150 deficiency promotes obesity-induced inflammation 
Chronic adipose tissue inflammation is a major phenotype in obesity and 
a causal factor for obesity-associated insulin resistance.5,80,139 Given the 
metabolic abnormalities observed in HFD-miR-150KO mice, we examined the 
inflammatory features in adipose tissues. Although HFD-miR-150KO mice 
displayed a similar degree of adiposity and comparable size of adipocytes to 
HFD-WT mice based on histological analyses (Figure 2.6A), miR-150 deficiency 
significantly enhanced markers of obesity-induced adipose tissue inflammation. 
This included increased abundance of TNFα, IL1β, and IL6 (Figure 2.6B), which 
was confirmed by findings of increased activities of c-Jun N-terminal kinases 
(JNK; Figure 2.6C) and nuclear factor-κB (NFκB) signaling pathways (Figure 
2.6D) in VAT of HFD-miR-150KO as compared to the VAT of HFD-WT control 
mice. Concomitantly, we detected an increase in concentrations of inflammatory 
cytokines and a decrease in anti-inflammatory IL10 in plasma of HFD-miR-
150KO mice (Figure 2.6E). In addition, HFD-miR-150KO mice had greater 
expression of CCL2 (Figure 2.6F) in VAT and increased concentrations of CCL2 
in plasma compared to HFD-WT mice (Figure 2.6G). Compared to HFD-WT 
mice, the abundance of anti-inflammatory adiponectin was significantly less in 
VAT of HFD-miR-150KO mice (Figure 2.6H). Collectively, these results indicate 
that in the context of a miR-150 null genotype, there is a significant increase in 
obesity-associated systemic inflammation.  
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Figure 2.6 miR-150 regulates obesity-induced inflammation. A, Hematoxylin 
and eosin (H&E) staining of visceral adipose tissue (VAT) sections suggested 
similar size of adipocyte between wild type (WT) and miR-150 knockout (miR-
150KO) mice. The adiposity was comparable among the mice on a high fat diet 
(HFD). B, miR-150 depletion resulted in increased expression of inflammatory 
cytokines tumor necrosis factor-α (TNFα), interleukin (IL) 1β, and IL6 in VAT of 
mice fed a HFD (n=3). C and D, Loss of miR-150 led to elevated activation of c-
Jun N-terminal kinases (JNK) and nuclear factor-κB (NFκB) signaling pathways 
in VAT of mice fed a HFD. MFI, medium fluorescence intensity. Western blots 
were performed with antibodies against p65 and phosphorylated p65 (Pp65). E, 
Concentrations of cytokines in plasma of mice fed a HFD were detected using 
the Bio-PlexTM Cytokine Assay (Bio-Rad). F and G, miR-150 deficient mice fed a 
HFD showed greater expression of chemokine (C-C motif) ligand 2 (CCL2) in 
VAT and concentration in plasma compared to the HFD WT mice (n=3). H, miR-
150KO mice on a HFD had greater abundance of adiponectin but not resistin in 
VAT compared to HFD WT mice (n=3). Data are presented as mean ± SEM. 
*P<0.05, **P<0.001, ***P<0.0001.  
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 miR-150 deletion alters adipose tissue inflammatory response and the 
proportion of B lymphocyte subtypes 
To determine cell lineages that are major mediators of miR-150 actions in 
the context of obesity, we examined expression patterns of miR-150 in various 
hematopoietic and metabolically active tissues in lean mice. Consistent with 
previous results,155 expression of miR-150 is high in most hematopoietic tissues, 
including lymph nodes, thymus and spleen, while low in white adipose tissues 
and skeletal muscle (Figure 2.7). Of note, the stress of HFD-induced obesity did 
not significantly alter the expression patterns of miR-150 in metabolic tissues, 
including liver, visceral fat depots, brown fat or muscle (Figure 2.8A). Given the 
crucial roles of immune cells in regulating obesity-associated insulin resistance 
and adipose tissue inflammation, we further evaluated expression of miR-150 in 
various adipose tissue cell compartments. As expected, mature adipocytes 
isolated from visceral fat expressed low amounts of miR-150 compared to 
mature B and T cells (Figure 2.8E). Interestingly, macrophages are a major 
immune cell population in stromal cells of adipose tissue in obese individuals, 
60,160,161 but they did not express high amounts of miR-150 as compared to 
lymphocytes (Figure 2.8E). 
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Figure 2.7 The expression of miR-150 in various tissues from lean wild 
type mice. The abundance of miR-150 in key hematopoietic or metabolic 
tissues of wild type lean mice was measured by reverse-transcription PCR 
analysis. The result indicated that hematopoietic tissues had high abundance of 
miR-150. Data are presented as mean ± SEM (n=3). 
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 Next, we examined the composition of immune cells in stromal cells 
isolated from VAT of HFD-miR-150KO and HFD-WT mice. Among all 
hematopoietic lineages examined, the proportion of CD4+ T cells, but not CD8+ 
T cells, was significantly higher in the miR-150 deficient than HFD-WT control 
mice (Figure 2.8B). Consistent with previous reports,93,160,162 macrophages are a 
major immune cell type in white adipose tissue of obese individuals that 
accounts for more than 30% of stromal cells (Figure 2.8B). Although total 
adipose tissue macrophages were comparable in HFD-miR-150KO and HFD-
WT mice, miR-150 depletion resulted in more proinflammatory M1 macrophages 
(F4/80+CD11b+CD206-CD11c+, P=0.002, Figure 2.8C) in adipose tissues.  
Given the high proportion of macrophages in adipose tissue niches and 
their contribution to the development of obesity-induced adipose tissue 
inflammation, we examined the impact of miR-150 ablation on polarization of 
macrophages. To exclude pre-exposure of in vivo adipose tissue to inflammatory 
factors, we adopted an ex vivo activation system using bone marrow derived 
macrophages.159 Interestingly, there was no detectable change in expression of 
activation-related cell surface markers in response to either classical or 
alternative stimuli on macrophages derived from either miR-150KO or wild type 
bone marrow cells (Figure 2.9). 
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 Interestingly, white adipose tissues from obese mice had a significantly 
higher portion of B lymphocytes that accounted for more than 30% of the total 
stromal cell population (Figure 2.8B). Although the percentages of total adipose 
tissue B cells were comparable in HFD-miR-150KO and HFD-WT mice, miR-150 
ablation resulted in significantly more B1a cells (CD19+CD5+CD43+, P=0.0006) 
in the visceral fat tissue (average of 17.5%, Figure 2.8D) compared to controls 
(average of 8.6%, Figure 2.8D). Ablation of miR-150 in mice specifically 
enhances B1 cell formation,156 a major B cell subtype in visceral adipose tissues. 
Thus, we hypothesized that exacerbated obesity-associated adipose tissue 
inflammation and insulin resistance due to miR-150 deficiency are, at least 
partially, attributable to alterations in the proportion of B lymphocyte subtypes. 
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Figure 2.8 miR-150 affects the activation of immune cells in adipose 
tissues of mice fed a high fat diet (HFD). A, Similar expression level of miR-
150 was detected in key metabolic tissues between HFD-fed and low fat diet 
(LFD)-fed mice (n=3). GI-fat, gastrointestinal fat. Epi-fat, epididymal fat. muscle, 
skeletal muscle. B, After HFD feeding, miR-150 knockout (miR-150KO) mice 
had greater proportion of CD4+ T cells in visceral adipose tissue (VAT) but 
similar population of B cells (B, CD19+), macrophages (M, F4/80+CD11b+), and 
CD8+ T cell (CD8+ T) compared to HFD-fed WT mice. C, There was greater 
proportion of M1 Adipose tissue macrophage (ATM) in vascular stromal cells 
(VSC) of VAT of HFD-fed miR-150KO mice, compared to HFD-fed WT mice. M1, 
F4/80+CD11b+CD206-CD11c+; M2, F4/80+CD11b+CD206+CD11c-. D, miR-
150KO mice fed a HFD had greater population of B1 and decreased proportion 
of B2 cells in VSC, compared to HFD-fed WT mice. B1a, CD19+CD5+CD43+; 
B1b, CD19+CD5+CD43-; B2, other CD19+ B cells. E, Adipose tissue resident 
CD3+ T cells and B220+ B cells showed high abundance of miR-150, while 
F4/80+ macrophages and adipocytes had low level of this microRNA (n=3). Data 
are presented as mean ± SEM. *P<0.05, **P<0.001.  
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Figure 2.9 Effects of miR-150 on macrophage activation. After stimulation 
with either interleukin 4 (IL4) (20 ng/mL) or lipopolysaccharide (LPS; 100 ng/mL), 
the activation of bone marrow-derived macrophages was measured by flow 
cytometry with antibodies against cell surface markers CD69, CD86, and CD80. 
The results indicate that miR-150 did not affect the activation of macrophages. 
Data are presented as mean ± SEM (n=3). 
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 miR-150 Is an important regulator for adipose tissue B cell function 
To determine the regulatory role of miR-150 in controlling B cell function, 
we examined its expression pattern during B cell activation. Naïve B cells 
isolated from spleens of 6 to 8 week-old wild type mice were stimulated using 
both T-cell independent (LPS) and T-cell dependent (CD4 & CD40) 
methodologies.163,164 Shortly after stimulation with LPS, there was a significant 
increase in expression of miR-150 in B cells that peaked during the first 24 hours 
and then decreased to levels comparable to those in naïve B cells after 48 hours 
(Figure 2.10A). Interestingly, miR-150 null B cells displayed an enhanced 
activation response to stimulation as evidenced by elevated activation of B cell 
receptor (BCR) signaling pathways and immunoglobulin production (Figure 
2.10B-D).165 This observation partially explained the elevated levels of plasma 
IgG and IgA in HFD-miR-150KO compared to HFD-WT mice (Figure 2.10E). 
Taken together, these results suggest that enhanced adipose tissue 
inflammation and exacerbated insulin resistance in obese miR-150KO mice is 
attributed to altered B cell functions.  
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Figure 2.10 miR-150 is an important regulator of B cell function in adipose 
tissue. A, The expression pattern of miR-150 in B cells upon activation (n=3). B 
and C, miR-150 knockout (miR-150KO) B cells exhibited greater production of 
IgA than that of wild type (WT) B cells after stimulation with lipopolysaccharide 
(LPS, 10 μg/mL) or interleukin 4 (IL4, 10 ng/mL)/CD40 (10μg/mL, n=9). D, miR-
150KO B cells (BmiR-150KO) showed greater activation of B cell receptor (BCR) 
signaling pathway compared to WT B cells (BWT) upon stimulation with LPS 
(n=3). E, The concentration of immunoglobulins (Ig) in plasma of WT and miR-
150KO mice on a high fat diet (HFD). Data are presented as mean ± SEM. 
*P<0.05. 
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 miR-150 deficiency-dependent insulin resistance is mediated by adipose 
tissue B cells  
To confirm the potential role of B cells in regulating obesity-associated 
insulin resistance, we utilized the adoptive transplantation model. B cells were 
isolated from HFD-miR-150KO and HFD-WT mice and injected into Bnull mice 
that harbor mutated immunoglobulin μ heavy-chain, resulting in an impaired 
capacity for production of mature B cells (Figure 2.11).158 Upon HFD feeding, 
Bnull mice had significantly less insulin resistance than HFD-WT mice, which is 
higher in glucose intolerance compare to wild type or Bnull mice fed the regular 
chow diet (LFD-WT, LFD-Bnull, Figure 2.12A). We isolated B220+ B cells from 
spleens of HFD-miR-150KO (HFD-Bnull-BmiR-150KO) and HFD-WT mice (HFD-Bnull-
BWT), and intraperitoneally injected a total of 1x107 cells into Bnull mice and 
maintained recipient animals on a HFD. Body weight gain, food intake and 
adiposity were not affected after two weeks of feeding the HFD with respect to 
either HFD-Bnull-BmiR-150KO or HFD-Bnull-BWT mice (Figure 2.13). Examination of B 
cells in the visceral white adipose tissue confirmed successful engraftment 
(Figure 2.12B). Importantly, recipient Bnull mice with adoptive transplants of wild 
type B cells displayed increased insulin resistance compared to mock transplant 
with PBS, which was further enhanced in recipients transplanted with miR-
150KO B cells from HFD fed mice (Figure 2.12C). Accompanied by impaired 
glucose tolerance and insulin resistance, the abundance of total IgG and IgA in 
plasma was also greater in HFD-Bnull mice engrafted with miR-150KO B cells 
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 than WT-B cells (Figure 2.12D). These results confirm that miR-150 deficiency-
induced insulin resistance is significantly influenced by B lymphocytes.  
 
 
 
Figure 2.11 The absence of mature B cells in Bnull mice. Viable CD19+ B 
cells in the spleen of C57BL/6 immunoglobulin μ heavy-chain knockout (Bnull) 
mice and wild type (WT) mice were analyzed by flow cytometry with antibodies 
against CD19. The result indicates the absence of viable CD19+ B cells in Bnull 
mice. Data are presented as mean ± SEM (n=6). 
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Figure 2.12 miR-150 deficiency-dependent insulin resistance is mediated 
by adipose tissue B cells. A, Glucose tolerance test analysis indicated that 
Bnull mice fed a high fat diet (HFD-Bnull) showed attenuated glucose intolerance 
compared to wild type (WT) mice on a HFD (HFD-WT; n=5-8). LFD-Bnull, Bnull 
mice was fed a low fat diet (LFD). B, The population of macrophages (M, 
F4/80+CD11b+), B cells (B, CD19+), CD4+ T cells (CD4+ T) and CD8+ T cells 
(CD8+ T), B cell subtypes, and macrophage subtypes in vascular stromal cells 
(VSC) of HFD-Bnull mice at 2-weeks after injection of B cells. C, Glucose 
tolerance test analysis indicated that HFD-Bnull mice with injection of miR-150KO 
B cells (HFD-Bnull-BmiR-150KO) had greater level of glucose intolerance compared 
to HFD-Bnull mice injected with WT B cells (HFD-Bnull-BWT, n=7-8). D, HFD-Bnull-
BmiR-150KO mice had greater levels of plasma total IgG and IgA compared to HFD-
Bnull-BWT mice. Data are presented as mean ± SEM. *P<0.05, **P<0.001, 
***P<0.0001. 
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Figure 2.13 Body weight and adiposity of Bnull mice fed a high fat diet (HFD) 
after B cell transplantation. The body weight and adiposity of HFD Bnull mice 
were measured after injection with either wild type (WT) B cells from HFD-WT 
(HFD-Bnull-BWT) or miR-150KO B cells isolated from HFD-miR-150KO mice 
(HFD-Bnull-BmiR-150KO). The results indicated that the HFD Bnull mice with 
transplantation of WT or miR-150KO B cells had similar the body weight and 
adiposity. Data are presented as mean ± SEM. 
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 miR-150 regulates obesity-associated insulin resistance and tissue 
inflammation by controlling B cell interactions with other immune cell 
components in the adipose tissue niche 
Results of previous studies suggest that B cells contribute to obesity-
associated insulin resistance through immunoglobulin production.110 In this study, 
higher levels of immunoglobulins were also observed in both HFD-miR-150KO 
and HFD-Bnull-BmiR150KO mice. To determine if insulin resistance observed in this 
model is partially attributable to alterations in immunoglobulin profiles secreted 
from B cells due to miR-150 depletion, we enriched plasma immunoglobulin and 
injected it into HFD-Bnull mice, which had impaired antibody production due to 
deficient B cell formation. Surprisingly, there was no a detectable difference in 
insulin resistance in HFD-Bnull mice that received immunoglobulin from either 
HFD-miR-150KO or HFD-WT control mice (Figure 2.14). These results suggest 
that the effects of miR-150 on obesity-induced insulin resistance are not related 
to production of pathogenic IgG antibodies. 
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Figure 2.14 Glucose tolerance test for Bnull mice on a high fat diet (HFD) 
after immunoglobulin (Ig) G injection. Bnull mice on a HFD were injected with 
IgG purified from plasma of miR-150KO mice (HFD-Bnull-IgGmiR-150KO) or WT 
mice (HFD-Bnull-IgGWT) fed a HFD. A glucose tolerance test was performed 1 
week after injection of IgG. The result indicated that the effects of miR-150 on 
obesity-induced insulin resistance are not related to production of pathogenic 
IgG antibodies. Data are presented as mean ± SEM (n=6).  
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 In addition to immunoglobulin production, B cells play important roles in 
immune responses through interacting with other cell types, such as T cells and 
macrophages.166,167 Therefore, we examined whether miR-150 deficient B cells 
could alter B cell interactions with other major populations of immune cells in 
adipose tissue. Indeed, we observed enhanced activation patterns of both T 
cells and macrophages; the two major cell types in adipose tissue stroma. Wild 
type CD4+ and CD8+ T cells displayed a higher response to CD3-CD28 
activation when co-cultured with activated miR-150KO B cells compared to wild 
type B cells, resulting in higher levels of activation-related surface markers and 
production of IFNγ and IL2 (Figure 2.15A and B). Although miR-150 depletion in 
macrophages did not alter their activation (Figure 2.9), proinflammatory M1 
macrophages co-cultured with miR-150KO B cells displayed a significantly 
enhanced proinflammatory activation profile, including increased expression of 
activation-related surface markers CD69 and CD80 and production of TNFα 
(Figure 2.15C and D). Taken together, these results explain the overall increase 
in adipose tissue inflammation in obese miR-150KO mice, and suggest that miR-
150 modulates adipose tissue inflammation induced by obesity by controlling B 
cell functions and their interactions with macrophages and T cells. 
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Figure 2.15 miR-150 regulates obesity-associated insulin resistance and 
tissue inflammation by controlling B cell interactions with other immune 
cells in adipose tissue. A and B, The activation of wild type (WT) CD4+ T cells 
(T4) or CD8+ T cells (T8) after co-culture with either WT B cells (BWT) or miR-
150knockout (miR-150KO) B cells (BmiR-150KO, n=3). C, The expression of 
macrophage activation-related surface markers after co-culture with B cells 
(n=3). D, The expression of macrophage activation-related genes after co-
culture with B cells (n=3). Data are presented as mean ± SEM. *P<0.05, 
**P<0.001. 
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 Several genes targeted by miR-150 mediate its regulation on B cell 
functions  
MicroRNAs exert their biological functions by either blocking translation 
and/or inducing degradation of the target mRNAs by base-pairing to the 
recognition sites.135,136 Previous studies have reported that Myb is an important 
target gene of miR-150 during B cell formation and activation.156,168-172 Utilizing 
prediction algorithms, TargetScan Mouse 6.2173 and PicTar174, we identified 
several additional genes bearing miR-150 target sites. Using a luciferase 
reporter assay, we confirmed that Elk1 and Etf1 are bona fide miR-150 target 
genes as evidenced by suppression in their luciferase activities in the presence 
of miR-150 (Figure 2.16A). In contrast, mutation of the miR-150 binding site in 
the 3’ untranslated regions (UTR) of Elk1 and Etf1 prevented inhibition of 
luciferase activity by miR-150 (Figure 2.16A). Expression of miR-150 target 
genes Elk1, Etf1, and Myb was also greater in miR-150KO B cells during in vitro 
activation (Figure 2.16B). To further evaluate the effects of target genes on B 
cell functions, we knocked down expression of these genes in isolated B cells 
with shRNA constructs. The knockdown efficacy was evaluated in transfected 
cells by quantitative PCR analysis (Figure 2.16C and D). Intriguingly, knockdown 
of Myb, Etf1, Elk1, or all three target genes significantly decreased activation of 
B cells via BCR signaling pathways and production of IgA, as compared to miR-
150KO B cells with an empty vector (Figure 2.16E and F). In addition, there 
were similar effects on B cell activation in response to knockdown of Myb, Etf1, 
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 or Elk1, or all three target genes in miR-150KO B cells (Figure 2.17). These 
results demonstrated that Myb, Elk1 and Etf1 are bona fide targets of miR-150, 
which play critical roles in mediating miR-150 effects on B cell functions. 
 
Figure 2.16 miR-150 controls B cell functions through multiple target 
genes. A, Reporter constructs containing a 3’ untranslated region (UTR) with 
wild type (WT) or mutated miR-150 binding sites of target genes (mut; n=3). B, 
After 72-hour activation, the expression of miR-150 target genes in WT or miR-
150kockout (miR-150KO) B cells (n=3). C and D, Knockdown of miR-150 target 
gene expression in B cells by short hairpin RNA (shRNA) assay (n=3). E, The 
activation of B cell receptor (BCR) signaling pathways in miR-150KO B cells with 
knockdown of miR-150 target genes (n=3). F, IgA production by miR-150KO B 
cells with knockdown of miR-150 target genes (n=6). Data are presented as 
mean ± SEM. *P<0.05, **P<0.001, ***P<0.0001. Elk1, ETS domain-containing 
protein. Myb, myeloblastosis oncogene. Etf1, eukaryotic translation termination 
factor 1.  
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Figure 2.17 IgA production by B cells after knockdown of miR-150 target 
genes. IgA production by miR-150 knockout (miR-150KO) B cells after 
knockdown of miR-150 target genes was detected by flow cytometry with 
antibodies against CD19 and IgA after activation. The results indicated that 
knockdown of ELK1, ETF1, Myb or all of these three genes (COM) had similar 
effects on the IgA production by miR-150KO B cells. Data are presented as 
mean ± SEM (n=6). Elk1, ETS domain-containing protein. Myb, myeloblastosis 
oncogene. Etf1, eukaryotic translation termination factor 1. 
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 Discussion 
Chronic adipose tissue inflammation is a major pathogenic phenotype 
associated with obesity.5,80,139-141 Dramatic increases in immune cell populations 
and enhanced inflammatory functions alter the adipose tissue phenotypes to 
exacerbate pre-diabetic conditions, including systemic insulin resistance and 
inflammation.44,107,110,142,143 Comparing other immune cell lineages in adipose 
tissue niches relevant to the diabetic condition, B cells contribute more than 20% 
of the stromal cell population. However, their overall impact on physiological 
alternations, both metabolic and inflammatory, and mechanisms underlying their 
action in adipose tissues of obese individuals are poorly defined. Results of this 
study revealed that miR-150, a hematopoietic specific microRNA, exerts 
regulatory effects on B cell formation and function, and it is a novel regulatory 
factor for obesity associated adipose tissue inflammation and insulin resistance.  
Previous research, including ours, identified several hematopoietic 
specific microRNAs including miR-150, which is a critical regulator for B cell 
formation.155,156 Ectopic expression of miR-150 in all tissues or in hematopoietic 
stem cells, significantly and specifically impairs development of B lineage cells 
by blocking the transition from pro-B to pre-B stages.155 Interestingly, deletion of 
miR-150 resulted in a milder phenotype overall with elevated B1 cell production, 
but non-detectable changes in other hematopoietic lineages or non-
hematopoietic tissues.156 Although B1 cells account for less than 5% of the total 
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 B cells in circulation,152,157 they are one of the major immune cell types in 
peritoneal fluid and tissues.147,149,152 Thus, the miR-150 knockout mouse is a 
unique animal model to investigate the impact of B cells, including B1 cells, on 
development of chronic inflammation and insulin resistance in response to the 
stress of obesity. Indeed, we observed exacerbated pre-diabetic conditions, 
including elevated levels of insulin and cytokines, in miR-150KO mice compared 
to wild-type controls fed a HFD. Further, we now confirm that B1 cells are a 
major immune cell lineage in adipose tissue, accounting for 3% in lean mice and 
significantly increased to 8% in obese mice (Figure 2.8D). In addition, mice with 
miR-150 deficiency displayed even a higher proportion of B cell infiltration into 
adipose tissue represented by 77% B2, 16% B1a, and 7% B1b cells (Figure 
2.8d). Further, deletion of miR-150 in B cells significantly altered B cell activation 
in response to both T cell-dependent and T cell-independent stimuli with respect 
to increasing activation of BCR signaling pathways and immunoglobulin 
production (Figure 2.10).  
Given that previous studies suggest a minimal impact of miR-150 
deficiency on T cell formation and activation,156 we examined the potential 
impact of the miR-150 mutation in macrophages, the major immune cell 
population in adipose tissue niches. Interestingly, loss of miR-150 in 
macrophages did not alter macrophage polarized activation states with respect 
to activation related surface markers.  
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 Our adoptive transplantation model of Bnull mice allowed the 
determination that transfer of B cells from HFD-miR150 or HFD-WT partially 
recapitulates insulin resistance characteristic of miR-150 mutant mice (Figure 
2.12C). Winer et al. suggested that immunoglobulin production by B cells 
contributes to insulin resistance;110 however, we failed to observe such an effect 
in response to purified immunoglobulin (primarily IgG with a small portion of IgA 
and others) from HFD-miR-150KO or HFD-WT mice. We observed that B cells 
lacking miR-150 displayed a slight increase in immunoglobulin production, which 
could partially contribute to higher circulating levels of IgG and IgA in plasma of 
mice fed a HFD. However, the specific contribution of immunoglobulin 
production by B cells, especially adipose tissue B cells, to the development of 
insulin resistance needs to be investigated further. Taken together, our results 
suggest that adipose tissue B cells, including the B1 subtype, are primary 
contributors to enhanced adipose tissue inflammation and systemic insulin 
resistance in obese miR-150KO mice. 
Although loss of miR-150 did not significantly alter macrophage and T cell 
activation states under obesity stress directly (Figure 2.9),156 an enhanced 
overall proinflammatory profile was detected (Figure2.6). We confirmed that 
miR-150KO B cells can enhance both T cell and macrophage activation profiles 
(Figure 2.15) which can impair insulin tolerance in adipose tissue with 
transplanted B cells lacking miR-150 (Figure 2.12C). In addition, enhanced T cell 
and macrophage infiltration into adipose tissue in the adoptive transplantation 
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 model suggests that adipose tissue B cells are a potent source of cytokines for 
recruitment of immune cells to adipose tissue under the stress of obesity. 
Together with increased T cells and macrophages, adipose tissue B cells 
exacerbate obesity induced chronic inflammatory features in adipose tissue and 
subsequent systemic insulin resistance (Figure 2.18). 
Our understanding of the contributions of B cells to adipose tissue 
functions, especially under the stress of obesity, is in its infancy. In this study, 
we demonstrate that miR-150, a B cell specific regulatory microRNA, is a critical 
modulator of the pathogenesis of chronic tissue inflammation and insulin 
resistance associated with obesity, which are major contributors to metabolic 
syndrome and development of type 2 diabetes and other cardiovascular 
complications. Simultaneous targeting of multiple targets of miR-150 can exert a 
potent impact by shifting the signaling network governing adipose tissue B cell 
function, which can, in turn, change the adipose tissue niche and its function. 
Further investigations regarding the mechanisms of action of miR-150 and B 
cells will provide important information toward development of therapeutic 
strategies to alter microRNAs and modulate B cells to treat obesity-associated 
complications. 
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Figure 2.18 Schematic model of miR-150-mediated molecular network in B 
cells. miR-150 directly suppresses the expression of target genes, Elk1, Myb, 
Etf1, which are critical mediators of the activation of B cell receptor (BCR) 
signaling cascade. This miR-150-mediated B cell function is also critical for the 
activation of CD4+ T cells and macrophages residing in adipose tissues, 
eventually exerting profound impacts on the function of adipocytes. Elk1, ETS 
domain-containing protein. Myb, myeloblastosis oncogene. Etf1, eukaryotic 
translation termination factor 1. SYK, spleen tyrosine kinase. LYN, tyrosine-
protein kinase. ERK, extracellular regulated MAP kinase. PI3K, phosphoinositide 
3-kinase. PKC, protein kinase C. BLNK, B-cell linker. BTK, Bruton’s tyrosine 
kinase. PLCγ2, phospholipase C, gamma 2. VAV, guanine nucleotide exchange 
factor. 
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 CHAPTER III 
REGULATORY AXIS OF PPARγ-MIR-223 IN CONTROLLING 
ACTIVATION OF ADIPOSE TISSUE MACROPHAGES 
Adipose tissue macrophages (ATMs) are a critical cellular component for 
adipose tissue function. We recently reported that miR-223 is a potent regulator 
for activation of ATMs that favors an anti-inflammatory M2 phenotype. However, 
it is unclear if the regulation of miR-223 and subsequent interactions are 
consistent with known regulatory signaling pathways. I sought to determine the 
regulatory mechanism controlling miR-223 expression during ATM polarization, 
with a focus on PPARγ-dependent M2 activation. By employing both in vivo and 
in vitro models, I demonstrated that miR-223 is a critical mediator for PPARγ 
action in controlling M2 ATM activation, and subsequent beneficial effects to 
mitigate tissue inflammation and insulin resistance. I observed impaired PPARγ 
functions in miR-223KO mice with respect to suppression of inflammation and 
insulin sensitivity. I further demonstrated that miR-223 is a key mediator of 
PPARγ-regulated macrophage activation. Disruption of miR-223 in macrophages 
impaired PPARγ-dependent M2 activation, whereas over-expression of miR-223 
further enhanced M2 activation in response to PPARγ activation. Genomic 
screening of the miR-223 promoter identified three PPARγ-regulatory elements 
followed by confirmation with chromatin immunoprecipitation analysis and a 
luciferase reporter assay. My results revealed that two new miR-223 target 
81 
 
 genes, Rasa1 and Nfat5, are crucial regulators of M2 activation via the PPARγ-
miR-223 axis. This study provides the first evidence supporting a crucial role for 
the PPARγ-miR-223 axis in controlling activation of ATMs under the stress of 
obesity. In addition, identification of novel target genes in this context provided 
new genes for development of therapeutics agent to mitigate obesity related 
diseases. 
Introduction 
Adipose tissue resident macrophages (ATMs) exhibit heterogeneous 
phenotypes in response to various microenvironmental signals, ranging from 
proinflammatory M1 activation to anti-inflammatory M2 responses.175,176 Upon 
stimulation by T helper type 1 (Th1) cytokines, lipopolysaccharide (LPS) or free 
fatty acids, ATMs exhibit proinflammatory M1 responses,13,60 whereas Th2 
cytokines, including interleukin 4 (IL4) and IL13, induce activation of anti-
inflammatory M2 ATMs.66,67 The polarized activation status of ATMs is critical for 
maintaining adipose tissue homeostasis. In the context of obesity, ATMs 
preferentially undergo proinflammatory M1 activation, which propagates the 
chronic inflammatory status and insulin resistance.43,177,178 However, the 
regulatory mechanisms underlying activation of ATMs has not been fully 
elucidated. 
Peroxisome proliferator-activated receptor γ (PPARγ), a nuclear 
transcription factor, exerts profound functions that control polarized activation of 
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 ATMs. Activation of the PPARγ signaling pathway in ATMs suppresses the 
proinflammatory M1 phenotype by blocking activation of the nuclear factor κB 
(NFκB) cell signaling pathway.68-70 Activated PPARγ also induces expression of 
M2 response-related genes which involve fatty acid metabolism and 
mitochondrial activities.66,179-182 Furthermore, the PPARγ-mediated activation 
pattern of ATMs is sufficient to regulate adipose tissue functions and insulin 
resistance under the stress of obesity.66,183,184 Deletion of PPARγ in ATMs 
results in increased M1 activation and blunted M2 responses, which in turn 
exacerbates adipose tissue inflammation and reduces insulin sensitivity.66 
Our recent study identified microRNA-223 (miR-223) as an important 
regulator of activation of ATMs favoring the anti-inflammatory M2 phenotype.93 
ATMs with miR-223 deletion elicited an enhanced proinflammatory M1 
phenotype, but less anti-inflammatory M2 responses under the stress of obesity. 
This resembles the phenotypes derived from knockout of PPARγ in 
macrophages. Furthermore, the exacerbated adipose tissue inflammation and 
systemic insulin resistance associated with type 2 diabetes were driven by 
alterations in patterns of activation of ATMs in miR-223KO mice. These results 
demonstrate that miR-223 exerts protective effects on the pathogenesis of 
obesity-associated metabolic disorders through controlling ATM activation. 
However, the regulatory mechanism for miR-223 expression during ATMs 
polarized activation, and interactions of miR-223 with the regulatory signaling 
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 pathways governed by key regulators such as PPARγ in responding to stimuli in 
the obese tissue niche are not established.  
In this study, we demonstrated the miR-223 is required for PPARγ action 
and, in turn, ATM activation and subsequent insulin sensitivity under the stress 
of obesity. In addition, we identified three PPARγ regulatory elements located in 
the promoter region of the miR-223 gene, suggesting that a PPARγ-miR-223 
regulatory axis modulates ATM polarization, hence controlling immune 
homeostasis of the adipose tissue niche.  
Materials and Methods 
Animal experiments 
The generation of miR-223 deficient (miR-223KO) mice has been 
described previously.185 Wild-type (WT) C57BL/6J mice were used as controls. 
All mice were maintained on a 12/12-hour light-dark cycle. Male mice 5 to 6 
weeks of age were fed ad libitum. Mice were fed a high-fat diet (HFD; Cat. No. 
D12492, Research Diets, Inc; Table A-1). After 12-week feeding, either 
pioglitazone (10 mg/kg/day; stimulating PPARγ activation; ACTOS®)186 or 
phosphate buffered saline (PBS) was delivered into HFD-fed mice via 
intragastric injection for 4 weeks. After the feeding regimen, mice were subjected 
to phenotypic characterization and metabolic assays, including measurement of 
metabolic parameters in plasma, as well as insulin and glucose tolerance tests. 
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 All study protocols were reviewed and approved by the Institutional Animal Care 
and Use Committee of Texas A&M University. 
Isolation of stromal cells, mature adipocytes, and macrophages from 
visceral adipose tissues (VATs) 
The visceral adipose tissues were mechanically dissected and then 
digested with collagenase II (2 mg/mL; Cat. No. 17101-015, Invitrogen; Table A-
3) for 30 min at 37oC. After lysing red blood cells and passing the cells through a 
200-μm cell strainer, visceral fat stromal cells (VSC) and mature adipocytes 
were separated by centrifugation at 1000 x g for 5 min. To purify ATMs, VSC 
were incubated with biotin-labeled antibody against F4/80 (Cat. No. 13-4801-85, 
eBioscience) for identification of macrophages. Magnetic beads conjugated with 
streptavidin (Cat. No. 557812, BD Biosciences) were applied for isolation of 
macrophages. 
Macrophage differentiation and polarization 
Bone marrow-derived macrophages (BMDMs) were prepared as 
previously described.160 Macrophage maturation was examined by flow 
cytometry with antibodies against cell surface markers F4/80 (Cat. No. 53-4801-
82, eBioscience) and CD11b (Cat. No. 12-0112-83, eBioscience). BMDMs were 
stimulated with LPS (100 ng/mL) for M1 activation or IL4 (20 ng/mL) for M2 
activation. To enhance activation of PPARγ, BMDMs were treated with 
pioglitazone (1 μM).187 BMDMs were treated with a PPARγ antagonist, GW9662 
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 (0.1 μM; Cat. No. 70785, Cayman Chemical) to suppress activation of 
PPARγ.188  
Flow cytometry analysis 
The VSC, ATMs, and BMDMs were stained with fluorescence-tagged 
antibodies (0.125 μg/106 cells) to detect cell lineages. Myeloid cells were 
detected using antibodies against cell surface antigens F4/80 (Cat. No. 11-4801-
82, eBioscience), CD11b (Cat. No. 45-0112-82, eBioscience) and Gr-1 (Cat. No. 
35-5931-82, eBioscience); macrophage subtypes were detected with antibodies 
against cell surface markers F4/80, CD11b, CD206 (Cat. No. 141706, 
Biolegend), CD11c (Cat. No. 12-0114-82, eBioscience). Macrophage activation 
was measured with antibodies against cell surface proteins CD80 (Cat. No. 17-
0801-82, eBioscience), CD69 (Cat. No. 45-0691-82, eBioscience), and CD86 
(Cat. No. 11-0862-82, eBioscience). Data were analyzed using Flowjo software 
or Accuri C6 software (BD Biosciences) or Kluza software (Beckman Coulter). 
Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) 
analysis 
Total RNA was extracted from VATs, ATMs, adipocytes and BMDMs 
using the Trizol extraction protocol according to the manufacturer’s instructions 
(Cat. No. R2050, Zymo Research). Gene expression analysis was performed 
using a iScript One-Step RT-PCR kit with SYBR Green (Cat. No. 170-8893, Bio-
Rad) on Bio-Rad CFX384 (Bio-Rad). The data presented correspond to the 
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 mean of 2-ΔΔCt from at least three independent experiments after being 
normalized to β-actin. 
Chromatin immunoprecipitation (ChIP) assay 
ChIP assays were performed as described previously.189 Briefly, BMDMs 
were cross-linked for 10 min with 1% formaldehyde and quenched with 125 mM 
glycine (Table A-5). After nuclei were isolated by centrifugation, the pellet was 
resuspended in lysis buffer containing 0.1% SDS and sonicated to achieve 
fragment sizes of 200-600 bp by Bioruptor® Pico (diagenode). The 
immunoprecipitation was conducted with ChIP-grade protein G magnetic beads 
(Cat. No. 9006S, Cell Signaling) using an antibody against PPARγ (Cat. No. 
ab41928, Abcam). IgG protein (Cat. No. ab18413, Abcam) was used as the 
negative control. To validate the enrichment, quantitative PCR was performed 
with tiled primers. 
Bio-Plex protein expression assay 
The concentrations of TNFα, IL1β, and IFNγ in plasma were determined 
using a Bio-PlexTM Cytokine Assay (Cat. No. M60-009RDPD, Bio-Rad). 
Concentration of insulin in plasma was determined using the Bio-Plex Pro 
Mouse Diabetes Insulin set (Cat. No. 171-G7006M, Bio-Rad). The abundance of 
total (Cat. No. 171-V60007M, Bio-Rad) and phosphorylated (Cat. No. 171-
V50011M, Bio-Rad) c-Jun N-terminal kinases (JNK) and phosphorylated P65 
(Cat. No. 171-V50013M, Bio-Rad) in VAT was determined using the Bio-Plex 
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 Cell Signaling Magnetic Assays (Bio-Rad). β-actin was used as the internal 
control. These Bio-Plex assays were performed using the Bio-Plex MAGPIXTM 
multiplex reader (Bio-Rad). Results were analyzed using Bio-Plex Data ProTM 
software (Bio-Rad). 
Luciferase reporter assay 
The luciferase reporter assay was carried out as described previously.93 
To verify that PPARγ binds to the upstream region of pre-miR-223, a 1732-bp 
DNA fragment (-3849 to -2117 relative to the 5’ end) within the upstream region 
of the pre-miR-223 gene was inserted into upstream of the SV40 promoter of the 
pGL3 promoter vector (Promega). The luciferase activity was determined by 
transient transfection of the murine macrophage cell line RAW264.7 with Bright-
Glo luciferase reporter system (Promega) and normalized to the internal control 
firefly luciferase activity. The full 3’-untranslated region (3’-UTR) sequence of 
these genes or at least the 250 bp flanking region of the predicted miR-223 
binding site was cloned into the psiCheck2 Vector (Promega) downstream of the 
Renilla luciferase-coding region. To validate the suppressive effects of miR-223, 
the reporter constructs were co-transfected with miR-223 mimic oligonucleotides 
or negative control oligonucleotides into HEK293 cells. After 48 h co-transfection, 
the activities of Renilla luciferase were measured using the Dual-Glo luciferase 
reporter system (Cat. No. E2920, Promega) and normalized to the internal 
control firefly luciferase activity. Repressive effects of miR-223 on target genes 
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 were plotted as the percentage repression in three biological repeats that each 
contained three technical repeats. 
Lentiviral shRNA assay 
The pLKO.1-CMV-TurboGFPTM vector (Sigma-Aldrich) with inserted short 
hairpin RNA (shRNA; targeting Nfat5 and Rasa1) was co-transfected with 
compatible packaging plasmids into HEK293T cells. The lentiviral supernatants 
were collected 72 h after transfection and used to infect BMDMs. The empty 
vector was used as the control. 
Data and statistical analyses 
Results are expressed as means ± SEM. Each data point derived from 
RT-PCR assays represents an average of two technical replicates, and data 
were averaged over independently replicated experiments (n=3-4 independently 
collected samples) and analyzed using the Student’s t test. The overall group-
effect was analyzed for significance using two-way ANOVA and the Bonferroni 
post-test for each factor at each individual time. Data analyses were performed 
using Graphpad Prism version 6.0 software. A value of P<0.05 was considered 
statistically significant. 
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 Results 
miR-223 Is required for PPARγ-dependent activation of adipose tissue 
macrophages under obesity-induced stress 
As an insulin sensitizer, PPARγ activation improves obesity-associated 
metabolic abnormalities.190-192 Indeed, after administration of the PPARγ agonist 
pioglitazone for 4 weeks, high fat diet-fed wild type mice (HFD-WT-pio) showed 
a remarkable improvement in insulin sensitivity based on results from both the 
glucose tolerance test and the insulin tolerance test (Figure 3.1A and B). In 
addition, HFD-WT-pio mice had reduced hyperglycemia and hyperinsulinemia 
compared to HFD-WT mice (Figure 3.1C). No significant changes were 
observed in body weight gain and food intake among the HFD-fed mice (Figure 
3.2). The improved insulin sensitivity was accompanied with the attenuated 
inflammatory responses.177 As expected, we observed reduced inflammatory 
responses in visceral fat depots of HFD-WT-pio mice, as evidenced by 
decreased activities of JNK and NFκB signaling pathways and expression of 
inflammatory cytokines (Figure 3.1D-F). Concomitantly, we detected a significant 
decrease in concentrations of inflammatory cytokines including TNFα and IL1β 
in plasma of HFD-WT-pio mice compared to HFD-WT mice (Figure 3.1G). 
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Figure 3.1 Enhanced activation of PPARγ improves obesity-associated 
adipose tissue inflammation and insulin sensitivity in wild type (WT) mice 
and WT mice treated with pioglitazone (WT-pio) on a high fat diet (HFD). A 
and B, results of glucose tolerance and insulin tolerance tests (n=9-10) indicate 
PPARγ promotes insulin sensitivity of obese mice. C, Concentrations of glucose 
and insulin were less in plasma of WT mice fed a HFD with PPARγ agonist 
pioglitazone treatment (HFD-WT-pio) than that of obese without pioglitazone 
treatment (HFD-WT) but no difference when mice were fasted for 16 hours. D, 
Expression of genes for proinflammatory cytokines tumor necrosis factor-α 
(TNFα), interleukin (IL)1β, and IL6 was reduced in visceral adipose tissue (VAT) 
of WT-pio mice fed a HFD (n=3). E and F, Activation of c-Jun N-terminal kinases 
(JNK) and nuclear factor-κB (NFκB) signaling pathways in VAT was repressed 
after administration of pioglitazone. MFI, medium fluorescence intensity. G, 
Concentrations of proinflammatory cytokines in plasma of mice fed a HFD were 
decreased after administration of pioglitazone. IFNγ, interferon γ. Data are 
presented as mean ± SEM. *P<0.05, **P<0.001. 
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Figure 3.2 Body weight (BW) gain and food intake. After being fed a high fat 
diet (HFD) for 12 weeks, wild type (HFD-WT-pio) and miR-223 deficient (HFD-
miR-223KO-pio) mice were given daily intragastric injection of pioglitazone (10 
mg/kg/day) or phosphate buffered saline (PBS) for an additional 4 weeks. Body 
weight and food intake of mice were recorded every week during the feeding 
regimen. The results indicated that PPARγ activation had minimal effects on 
weight gain and food intake of obese mice. Data are presented as mean ± SEM 
(n=9-10). 
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 In the context of obesity, enhanced activation of PPARγ significantly 
suppresses inflammatory responses of ATMs and this is critical for attenuating 
inflammation in adipose tissue. After administration of pioglitazone for 4 weeks, 
we observed comparable populations of ATMs between HFD-WT and HFD-WT-
pio mice, accounting for about 30% of stromal cells (Figure 3.3A). This indicates 
that activation of PPARγ had minimal effects on the infiltration of macrophages 
into VAT of HFD-fed mice. However, PPARγ-dependent responses included a 
decrease in the proportion of proinflammatory M1 ATMs and increased M2 
ATMs in VAT of HFD-fed WT mice treated with pioglitazone (Figure 3.3A). 
Interestingly, expression of miR-223 was induced in ATMs, but not adipocytes of 
HFD-WT mice after treatment with pioglitazone for 4 weeks (Figure 3.3B). These 
results suggest that miR-223 plays a role in the PPARγ-dependent cell signaling 
pathway that modulates activation of ATMs. 
We further investigated the impact of miR-223 on PPARγ action to 
regulate ATM activation using miR-223 deficient (miR-223KO) mice. Intriguingly, 
in contrast to the suppression on proinflammatory M1 responses in ATMs 
observed in HFD-WT-pio mice (Figure 3.3A), the activation pattern for ATMs 
was similar between HFD-miR-223KO mice and HFD-miR-223KO-pio mice 
(Figure 3.4A), suggesting that miR-223 depletion impaired the ability of PPARγ 
to modulate the activation status of ATMs. We also observed that the 
exacerbated inflammatory responses observed in HFD-miR-223KO mice were 
not fully recovered by pioglitazone treatment, as judged by comparable degrees 
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 of activation of JNK/NFκB signaling pathways and production of proinflammatory 
cytokines (Figure 3.4B-E). In addition, pioglitazone treatment attenuated glucose 
intolerance, but not insulin resistance of HFD-miR-223KO mice (Figure 3.4F-G). 
Thus, these results suggest that loss of miR-223 impairs PPARγ functions that 
mediate activation of ATMs and subsequent inflammatory responses and insulin 
resistance. 
 
Figure 3.3 The expression of miR-223 is induced via PPARγ-mediated 
activation of adipose tissue macrophages. A, The population of 
macrophages (F4/80+CD11b+) and their subtypes in vascular stromal cells 
(VSC) of visceral adipose tissue (VAT) from mice fed a high fat diet (HFD). M1, 
F4/80+CD11b+CD206-CD11c+; M2, F4/80+CD11b+CD206+CD11c-. B, The 
expression of miR-223 in adipocytes and ATMs of mice fed a HFD was induced 
due to treatment with pioglitazone. Data are presented as mean ± SEM (n=3). 
*P<0.05.  
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Figure 3.4 A deficiency in miR-223 impairs PPARγ functions in modulating 
adipose tissue functions and macrophage activation under the stress of 
obesity. A, The population of macrophage and its subtypes in visceral adipose 
tissue (VAT) were comparable between miR-223KO mice fed a high fat diet 
(HFD) with or without treatment with pioglitazone (HFD-miR-223KO-pio, HFD-
miR-223KO). B, Pioglitazone treatment did not fully repress the expression of 
genes for proinflammatory cytokines TNFα, IL1β, and IL6 in VAT of miR-223KO 
mice fed a HFD (n=3). C and D, Activation of JNK and NFκB signaling pathways 
in VAT were similar between HFD-miR-223KO and HFD-miR-223KO-pio mice. 
MFI, medium fluorescence intensity. E, Concentrations of proinflammatory 
cytokines in plasma of miR-223KO mice fed a HFD were decreased after 
administration of pioglitazone. F and G, Results of glucose tolerance test and 
insulin tolerance test indicated that pioglitazone treatment failed to fully recover 
the insulin sensitivity of miR-223KO mice fed a HFD (n=9-10). Data are 
presented as mean ± SEM. *P<0.05, **P<0.001. 
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 The regulatory axis of PPARγ-miR-223 controls M2 responses 
Given the significant impacts of miR-223 on PPARγ-mediated activation 
of ATMs, we further explored the role of miR-223 in PPARγ signaling pathway 
using an ex vivo model with BMDMs. We observed that pioglitazone treatment 
further enhanced M2 responses of BMDMs induced by IL4, as evidenced by the 
increased expression of activation-related cell surface markers (WT-IL4+pio vs. 
WT-IL4; Figure 3.5A). However, BMDMs lacking miR-223 exhibited a blunted 
M2 response that was not fully rescued by pioglitazone treatment with respect to 
decreased the expression of activation-related surface marker CD69 and other 
key genes such as peroxisome proliferator-activated receptor gamma, 
coactivator 1 α (PGC1α), IL10, and arginase 1 (Figure 3.5A and B). This 
recapitulated the phenotypes of HFD-miR-223KO mice treated with pioglitazone 
(Figure 3.4A). Conversely, over-expression of miR-223 in BMDMs enhanced M2 
responses (WT-IL4 vs. miR223oe-IL4), which was similar to the improvement in 
expression of activation-related surface markers of WT BMDMs induced by 
pioglitazone treatment (miR223oe-IL4 vs. WT-IL4+pio; Figure 3.5C). Further, 
pioglitazone treatment increased the expression of activation-related cell surface 
marker CD69 in BMDMs with ectopic expression of miR-223 (miR223oe-IL4+pio 
vs. WT-IL4+pio; Figure 3.5C). Taken together, these results demonstrate that 
miR-223 acts as a critical component of the PPARγ-dependent signaling 
pathway that regulates activation of M2 macrophages.  
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Figure 3.5 miR-223 is required for PPARγ-dependent activation of 
alternative M2 macrophages. A, The expression of activation-related cell 
surface markers, CD69 and CD86, of bone marrow derived-macrophages 
(BMDMs) with wild-type (WT) and miR-223KO genotypes following stimulation 
with interleukin 4 (IL4) and wsith or without pioglitazone treatment (miR223KO-
IL4+pio, miR223KO-IL4). The WT BMDMs were the controls (WT-IL4, WT-
IL4+pio). B, A deficiency in miR-223 results in decreased gene expression of 
BMDMs upon stimulation with IL4 and pioglitazone. PGC1α, peroxisome 
proliferator-activated receptor gamma, coactivator 1 alpha; Arg1, arginase 1. C, 
The expression of activation-related cell surface marker of WT BMDMs with 
miR-223 overexpression (miR223oe) following IL4 stimulation, with or without 
treatment with pioglitazone (miR223oe-IL4+pio, miR223oe-IL4). Data are 
presented as mean ± SEM (n=3). *P<0.05, **P<0.001. Means with different 
superscript letters are significantly different (P<0.05).  
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 We confirmed the stimulatory effects of PPARγ activation on the 
expression of miR-223 in M2 macrophages by demonstrating increased 
expression of miR-223 in BMDMs treated with pioglitazone and IL4 compared to 
control M2 cells (Figure 3.6A). This result was consistent with the observed 
increase in miR-223 expression in ATMs of mice treated with pioglitazone 
(Figure 3.3B), suggesting that PPARγ may directly regulate miR-223 expression. 
Therefore, we screened 4 kilobases (kb) upstream of the miR-223 precursor 
gene (pre-miR-223) with JASPAR algorithms (http://jaspar.binf.ku.dk/) to identify 
PPARγ response elements (PPREs).193 There were eight predicted classical 
PPREs (AGG(A/T)CA) within the upstream region of pe-miR-223.194-196 The 
ChIP assay was used to further investigate PPARγ interactions with the PPREs. 
The protein/DNA complexes were stabilized by formaldehyde crosslinking and 
isolated from BMDMs stimulated with IL4 and pioglitazone, and the sonicated 
DNA fragments (200-500bp) were immunoprecipitated using an antibody against 
PPARγ. The enrichment of PPREs (-3816 to -3811, -3450 to -3445, or -2248 to -
2243, relative to the 5’ end of pre-miR-223 coding region) within 4kb upstream 
region of miR-223 precursor gene was verified by quantitative PCR with tiled 
primer pairs for determination of the precise location of each PPRE (Figure 
3.6B).  
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 Next, to determine the function of the PPREs as direct binding sites for 
PPARγ, we generated a luciferase reporter construct harboring the PPREs (-
3849 to -2117, relative to the 5’ end of pre-miR-223 coding region) upstream of a 
SV40 promoter-luciferase expression cassette. After being transfected into 
macrophage cell line RAW264.7, the luciferase activity produced from the 
recombinant construct bearing PPREs was significantly increased compared to 
the control vector in the presence of IL4 (Figure 3.6C). Supplementation of 
pioglitazone further enhanced the luciferase activity generated from the PPRE-
inserted constructs, but not the control vector in the transfected RAW264.7 cells 
stimulated by IL4 (Figure 3.6C). Thus, these results demonstrate that these 
three PPREs are the direct binding sites for PPARγ and that miR-223 is a 
PPARγ-regulated gene in M2 macrophages. 
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Figure 3.6 The expression of miR-223 is induced in PPARγ-dependent 
activation of M2 macrophages. A, miR-223 expression in bone marrow 
derived macrophages (BMDM) increased in the presence of interleukin (IL) 4 
(M2) with or without treatment with pioglitazone. B, After formaldehyde 
crosslinking and sonication, the protein/DNA complexes were 
immunoprecipitated with antibody against PPARγ. The enrichment of potential 
PPARγ response elements (PPREs) upstream of the miR-223 precursor gene 
(pre-miR-223) was validated by quantitative PCR using tiled primer pairs to 
determine the precise location of each PPRE. C, Luciferase activity of a reporter 
construct harboring the upstream region (-3849 to -2117 relative to the 5’ end) of 
pre-miR-223 or empty vector in the presence of IL4 with or without treatment 
with pioglitazone. Data are presented as mean ± SEM (n=3). *P<0.05, 
**P<0.001. 
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 Rasa1 and Nfat5 are genuine miR-223 target genes in PPARγ-dependent 
activation of M2 macrophages 
MicroRNAs exert their biological functions by either blocking translation 
and/or inducing degradation of the target mRNAs by base-pairing to the 
recognition sites.135,136 We previously identified a pro-diabetic gene Pknox1 as a 
bone fide miR-223 target gene that plays critical roles in modulating the function 
of miR-223 in M1 macrophages.93 However, pioglitazone treatment did not affect 
expression of Pknox1 in M2 cells (Figure 3.7A), suggesting that other miR-223 
target genes are required for the PPARγ-miR-223 regulatory axis for M2 
responses. Thus, using prediction algorithms, TargetScan Mouse 6.2 and 
PicTar,173,174 we screened more than 20 predicted target candidates harboring 
miR-223 target sites. Among these, Rasa1 and Nfat5 were identified as genuine 
miR-223 target genes, as evidenced by suppression of their luciferase activities 
in the presence of miR-223 (Figure 3.7B). In contrast, mutation of the miR-223 
binding site in the 3’-UTR of Rasa1 and Nfat5 prevented the inhibition of 
luciferase activity by miR-223 (Figure 3.7B). RT-PCR analysis revealed that 
expression of Rasa1 and Nfat5 were inversely correlated with miR-223 
abundance in ATMs of lean mice (Figure 3.7C). Interestingly, the abundance of 
Rasa1 and Nfat5 was less in M2 WT BMDMs, and pioglitazone treatment further 
suppressed their expression in M2 WT macrophages (Figure 3.7D). These 
results suggest the potential roles of Rasa1 and Nfat5 in regulating PPARγ-
dependent M2 macrophage activation.  
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Figure 3.7 Rasa1 and Nfat5 are genuine miR-223 target genes. A, The 
expression of Pknox1 in bone marrow derived macrophages (BMDM) was 
decreased in response to stimulation with interleukin 4 (IL4) (M2) compared to 
native BMDMs (M0), but pioglitazone (pio) treatment did not further reduce the 
expression of Pknox1 in M2 macrophages (M2+pio). B, The assay with reporter 
constructs containing a 3’ untranslated region (UTR) with wild type (WT) or 
mutated miR-223 binding site of target genes (mut) identified Nfat5 and Rasa1 
as the miR-223 target genes. C, The RT-PCR analysis indicated that abundance 
of Nfat5 and Rasa1 in adipose tissue macrophages (ATMs) was greater in miR-
223knockout (miR-223KO) lean mice compared to the WT lean mice. D, 
Expression of miR-223 target genes Rasa1 and Nfat5 M2 macrophages was 
decreased in M2 macrophages compared to M0 cells, and there were further 
inhibition on the expression of these genes in response to pioglitazone treatment. 
Data are presented as mean ± SEM (n=3). *P<0.05, **P<0.001, ***P<0.0001. 
Means with different superscript letters are significantly different (P<0.05). 
Rasa1, RAS p21 protein activator (GTPase activating protein) 1. Nfat5, nuclear 
factor of activated T-cells 5. 
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 We next examined the impact of miR-223 target genes Rasa1 and Nfat5 
on PPARγ-mediated activation of M2 macrophages. Utilizing shRNA constructs, 
the expression of the miR-223 target genes, Nfat5 and Rasa1, in miR-223KO 
BMDMs was significantly decreased compared to that for miR-223KO BMDMs 
transfected with an empty vector (Figure 3.8A). The expression of an M2 
activation-related gene, arginase 1, increased after knockdown of Rasa1 or 
Nfat5 in miR-223KO BMDMs (Figure 3.8B). In addition, knockdown of these 
miR-223 target genes resulted in enhanced M2 activation in response to IL4 
stimulation, as evidenced by significant increases in expression of activation-
related cell surface markers CD69 and CD86 (Figure 3.8C). Taken together, 
these results demonstrate that miR-223 target genes, Rasa1 and Nfat5, play 
critical roles in the regulatory axis of PPARγ-miR-223 to control activation of M2 
macrophages.   
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Figure 3.8 miR-223 controls M2 macrophage activation by modulating 
expression of multiple target genes. A, Knockdown of miR-223 target genes 
Rasa1 and Nfat5 expression in miR-223KO bone marrow derived macrophages 
(BMDM) by short hairpin RNA (shRNA) assay. B, The expression of arginase 1 
which is associated with activation of M2 macrophages increased in response to 
knockdown of miR-223 target genes Rasa1 or Nfat5. C, Expression of 
macrophage activation-related cell surface markers CD69 and CD86 in BMDMs 
increased following knockdown of miR-223 target genes Rasa1 or Nfat5 in the 
presence of IL4. Data are presented as mean ± SEM (n=3). *P<0.05, **P<0.001. 
Rasa1, RAS p21 protein activator (GTPase activating protein) 1. Nfat5, nuclear 
factor of activated T-cells 5. 
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 Discussion 
Adipose tissue macrophages exert profound impacts on the homeostasis 
of adipose tissues by responding to distinct stimuli with heterogeneous activation 
phenotypes.35,197,198 The ATMs with an M1 phenotype are crucial for promoting 
chronic inflammation induced by obesity and clearance of apoptotic 
adipocytes;42,199,200 whereas M2 ATMs are major coordinators of adipose tissue 
remodeling and repair with anti-inflammatory features.201,202 In the context of 
obesity, there is a dramatic increase in the infiltration of macrophages into white 
adipose tissues which account for more than 40% of the stromal cell population 
in visceral fat depots in obese individuals.43,60 Under obesity-induced stress, 
ATMs not only increase in number, but also display an increased M1/M2 ratio for 
macrophages which result in an overall enhancement of inflammation in adipose 
tissues leading to the development of systemic insulin resistance.80,176 
Polarization of ATMs is tightly regulated by a well-orchestrated network in which 
PPARγ plays a central role in controlling activation of ATMs.203 In addition, 
epigenetic regulators, including microRNAs, exert an additional layer of 
regulation in the regulatory network.57 Our previous study demonstrated that 
miR-223 is a potent regulator that controls the polarization of ATMs in response 
to distinct signals in the microenvironment.93 However, the interplay between 
microRNAs and PPARγ-regulated signaling pathway is unclear. Results of this 
study provided clear evidence for a key role for the PPARγ-miR-223 axis in 
modulating activation of M1 and M2 responses in both in vivo and ex vivo 
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 systems. Our findings revealed that PPARγ acts as an enhancer to promote the 
expression of miR-223 in ATMs upon M2 activation, and that miR-223 is a 
critical mediator for PPARγ-dependent effects for activation of ATMs.  
Upon stimulation with Th2 cytokines such as IL4 and IL13, activation of 
the PPARγ-mediated signaling pathway is essential for triggering M2 responses 
such as the induction of expression of arginase 1 and IL10 in ATMs.66 PPARγ 
can also act as a transcriptional repressor of the inflammatory responses of 
macrophages through interrupting activity of the NFκB signaling pathway.68-70 
Odegaard et al. reported that knockout of macrophage-specific PPARγ impairs 
M2 responses of ATMs, subsequently exacerbating obesity-associated insulin 
resistance.66 Results of our study demonstrated that ligand-induced activation of 
the PPARγ-mediated signaling pathway suppressed activation of 
proinflammatory M1 ATMs (Figure 3.3A). Thus, a decrease in the inflammatory 
responses of ATMs attenuates adipose tissue inflammation in the context of 
obesity.80,159,178 In this study, we detected suppressive effects of PPARγ on 
inflammatory responses of ATMs in adipose tissue and a decrease in systemic 
insulin resistance (Figure 3.1).  
The myeloid cell-specific miR-223 exhibits significant epigenetic functions 
to regulate macrophage activation through post-transcriptional suppression of 
expression of its target genes.93,204-206 The expression of miR-223 is increased 
significantly in response to M2 activation, but did not change during activation of 
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 M1 macrophages.93 More importantly, the induction of miR-223 favors activation 
of anti-inflammatory M2 macrophages.93 Conversely, miR-223 deficient 
macrophages exhibit hypersensitivity in M1 responses induced by LPS 
stimulation and delayed responses to Th2 cytokine stimulation. In addition, in 
our previous study, Pknox1 was validated as a miR-223 target gene mediating 
effects of miR223 to activate macrophages.93 In the diet-induced obesity mouse 
model, we observed that loss of miR-223 resulted in an increase in the 
proportion of M1 ATMs in HFD-fed mice compared to HFD-WT mice which 
confirms results of our previous study.93 Given that expression of miR-223 is 
critical for M2 macrophage responses, we identified PPARγ as a key regulator of 
expression of miR223. Using ChIP-qPCR, we confirmed that PPARγ interacts 
with three PPREs within the upstream region of the miR-223 precursor gene in 
macrophages (Figure 3.6B). Further, results of the luciferase reporter assay 
verified direct interactions between PPARγ and the three PPREs (Figure 3.6C), 
and demonstrated critical roles for the PPREs for induction of PPARγ-induced 
expression of miR-223 in macrophages. This accounts for the increased 
expression of miR-223 in ATMs in response to activation of PPARγ under 
obesity-induced stress. In addition, PPARγ exerts profound effects on various 
cell types, such as adipocytes, to modulate expression patterns of microRNAs 
during adipogenesis.207,208 
We further demonstrated that miR-223 is a critical downstream 
component in the PPARγ-dependent signaling pathway controlling ATM 
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 activation. Mice with miR-223 deficiency display impaired beneficial outcomes 
after administration of a PPARγ agonist, pioglitazone, compared to wild type 
control mice, suggesting miR-223 is a crucial mediator of PPARγ action. The 
important role of miR-223 in the PPARγ-regulated signaling network was further 
confirmed in the present study using the ex vivo macrophage polarization 
system. Deletion of miR-223 in macrophages delayed M2 activation which was 
not rescued by administration of the PPARγ agonist pioglitazone. In addition, 
overexpression of miR-223 further enhanced PPARγ-dependent M2 
macrophages with respect to cell-activation related surface markers, cytokine 
production, and gene expression. We also found that Rasa1 and Nfat5 were 
novel miR-223 target genes that have critical roles in miR-223 function on M2 
macrophage activation, as evidenced by enhanced M2 responses after 
knockdown of expression of these target genes. Therefore, these results 
suggest that the regulatory role of miR-223 in the PPARγ-mediated signaling 
pathway depends on a network involving the novel target genes Rasa1 and 
Nfat5. 
In this study, we have showed that the PPARγ-miR-223 regulatory axis is 
crucial for controlling activation status of ATMs and subsequent adipose tissue 
inflammation and insulin sensitivity (Figure 3.9). miR-223 and its target genes 
Rasa1 and Nfat5 act as the critical downstream components of the PPARγ-
mediated cell signaling pathway that regulates ATM activation. Furthermore, 
identification of novel miR-223 target genes Nfat5 and Rasa1 in this context 
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 provides new gene targets for development of drugs with the potential to 
mitigate obesity-related diseases. 
 
Figure 3.9 Schematic model of the PPARγ-miR-223 regulatory axis in 
controlling activation of M2 macrophages and subsequent adipose tissue 
inflammation and systemic insulin resistance under the stress of obesity. 
PPARγ acts an enhancer to promote the expression of miR-223 through 
interacting with PPREs. miR-223 is required for PPARγ action in inducing M2 
responses through controlling the expression of target genes Nfat5 and Rasa1. 
The PPARγ-miR-223 axis-mediated M2 responses can attenuate obesity-
associated adipose tissue inflammation and insulin resistance. PPARγ, 
peroxisome proliferator-activated receptor gamma. PPRE, PPARγ response 
element. RXR, retinoid X receptor. Rasa1, RAS p21 protein activator (GTPase 
activating protein) 1. Nfat5, nuclear factor of activated T-cells 5. 
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CHAPTER IV 
INTERFERON TAU ALLEVIATES OBESITY-INDUCED ADIPOSE 
TISSUE INFLAMMATION AND INSULIN RESISTANCE BY 
REGULATING MACROPHAGE POLARIZATION* 
Chronic adipose tissue inflammation is a hallmark of obesity-induced 
insulin resistance and anti-inflammatory agents can benefit patients with obesity-
associated syndromes. Currently available type I interferons for therapeutic 
immunomodulation are accompanied by high cytotoxicity. Therefore, in this 
study, we have examined anti-inflammatory effects of interferon tau (IFNT), a 
member of the type I interferon family with low cellular toxicity even at high 
doses. Using a diet-induced obesity mouse model, I observed enhanced insulin 
sensitivity in obese mice administered IFNT compared to control mice, which 
was accompanied by a significant decrease in secretion of proinflammatory 
cytokines and an increase in anti-inflammatory macrophages (M2) in adipose 
tissue. Further investigations revealed that IFNT is a potent regulator of 
macrophage activation that favors anti-inflammatory responses as evidenced by 
activation of associated surface antigens, production of anti-inflammatory 
cytokines, and activation of selective cell signaling pathways. Thus, my study 
demonstrates, for the first time, that IFNT can significantly mitigate obesity-
associated systemic insulin resistance and tissue inflammation by controlling 
*Reprinted with permission from “Interferon tau alleviates obesity-induced adipose tissue 
inflammation and insulin resistance by regulating macrophage polarization” by Ying W, 
Kanameni S, Chang C, Nair V, Safe S, Bazer FW, Zhou B, 2014, PLOS ONE, 9(6): e98835, 
Copyright [2014].  
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 macrophage polarization, and thus IFNT can be a novel bio-therapeutic agent 
for treating obesity-associated syndromes and type 2 diabetes. 
Introduction 
Obesity and its associated metabolic abnormalities, including insulin 
resistance and cardiovascular disorders, have reached epidemic proportions. 
Chronic low degree adipose tissue inflammation, accompanied by enhanced 
immune cell infiltration, is a hallmark of obesity and a crucial contributor to the 
pathogenesis of insulin resistance and metabolic diseases.5,44,80,107,110,139,142 The 
infiltrated immune cells play critical roles in modulating obesity-associated 
adipose tissue inflammation. Among them, macrophages account for up to 50% 
of the stromal cell population in adipose tissues of obese individuals and are 
critical regulators of adipose tissue functions.44,60,160,209,210 In addition, adipose 
tissue macrophages (ATMs) undergo a phenotypic switch from anti-inflammatory 
status (M2) in the adipose tissues of lean individuals to a proinflammatory (M1) 
status in adipose tissues of obese subjects, which results in the development of 
tissue inflammation and systemic insulin resistance.176 The classic 
proinflammatory responses of ATMs (M1) depend on Toll-Like Receptors (TLRs) 
and activation of nuclear factor κB (NFκB)/c-Jun N-terminal kinase (JNK), 
leading to the production of inflammatory cytokines.211 In contrast, activation of 
M2 ATMs leads to recruitment of peroxisome proliferator-activated receptor γ 
(PPARγ) or other transcription factors resulting in an anti-inflammatory 
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 status.66,161,212,213 Our recent study revealed that other molecules, such as 
microRNAs, can exhibit profound regulatory functions on macrophage 
polarization.93 Activation of M2 macrophages can improve systemic insulin 
sensitivity and protect against development of cardiovascular diseases and type 
2 diabetes.214,215 
Clinical studies show the anti-inflammatory treatments can benefit 
patients with systemic insulin resistance.3,216,217 Type I interferons have been 
used as anti-inflammatory therapies by suppressing production of inflammatory 
cytokines such as interleukin (IL)-1β and tumor necrosis factor α (TNF-α).218-220 
However, severe cell toxicities associated with currently available type I IFNs, 
such as IFN-α and -β (IFNA and IFNB),221,222 dramatically hinder their clinical 
application. Recent studies revealed that a member of type I IFN family, 
interferon tau (IFNT), exerts potent immunomodulatory effects with very low 
cytotoxicity even at high dosages, which provides support for a clinical 
application of IFNT.  
IFNT is a type I interferon produced exclusively by mononuclear 
trophectoderm cells of conceptuses of ruminant species and plays a central role 
for successful implantation and establishment of pregnancy.128 IFNT shares high 
protein structural similarities with other members of the type I interferon family, 
such as IFNA and IFNB and particularly interferon omega (IFNW).223 Compared 
with IFNA and IFNB that have been applied as clinical therapeutics, IFNT lacks 
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 their cytotoxicity even at high concentrations.224,225 IFNT can shift the immune 
profile from an inflammatory to an anti-inflammatory phenotype to mitigate 
against autoimmune-associated diseases.131,134 Here, we show that IFNT is a 
potent regulator of macrophage polarization that significantly suppresses 
obesity-associated adipose tissue inflammation and ameliorates systemic insulin 
resistance. Thus, this study provides important evidence, for the first time, 
toward understanding the regulatory mechanism of IFNT action in the context of 
obesity and indicates potential clinical applications for IFNT in treating obesity-
associated metabolic syndrome 
Materials and Methods 
Animals 
Male C57BL/6J mice, 6 weeks of age, were used for diet feeding and 
bone marrow isolation and macrophage activation analyses. All mice were 
maintained on a 12-/12-hour light-dark cycle and fed ad libitum. To induce 
obesity, mice were fed a high-fat diet (HFD; Cat. No. D12492, Research Diets, 
Inc) for 12 weeks. Mice fed on a low-fat diet (LFD; Cat. No. D12450B, Research 
Diets, Inc) served as controls. In the IFNT treatment, mice received recombinant 
IFNT via drinking water (8 µg/kg body weight/day) for 12 weeks.3 The IFNT (30-
45 ng/mL) delivered orally in drinking water (1.5 mL/10 g body weight/day) was 
detected in plasma of mice using a highly specific and sensitive 
radioimmunoassay (Figure 4.1).226 Glucose metabolism and insulin sensitivity of 
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 LFD and HFD mice were evaluated by measuring concentrations of glucose and 
insulin in plasma, and conducting glucose tolerance and insulin tolerance tests. 
The glucose tolerance and insulin tolerance tests were performed during week 
12 of the study, and there was a 6-day interval between these two tests. In 
addition, the glucose tolerance and insulin tolerance tests were performed 
between 8:00 AM and 10:00 AM for all mice. Blood samples were collected from 
the tail vein of un-anesthetized mice and stored in EDTA-coated tubes, and 
plasma was harvested after the blood was centrifuged at 1,000 x g for 15 min at 
4oC. At the end of the study, all mice were euthanized between 8:00 AM and 
10:00 AM by exposure to a high concentration of carbon dioxide (CO2). In this 
study, we combined the visceral adipose tissues (VAT; retroperitoneal fat, peri-
renal fat, mesenteric fat, peri-gonadal fat) for isolation of mature adipocytes, 
measurement of gene expression, immunohistochemistry, and evaluation of 
immune cell infiltration. The VAT from mice were fixed in fresh 4% 
paraformaldehyde and used for immunohistochemical analysis or snap frozen in 
liquid nitrogen and stored at -80oC. All study protocols were approved by the 
Institutional Animal Care and Use Committee of Texas A&M University. 
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Figure 4.1 Plasma level of interferon tau (IFNT). Concentrations of IFNT in 
plasma of mice fed a high fat diet were determined by radioimmunoassay after 
12 weeks of treatment with IFNT in drinking water (8 μg/kg/day). Data are 
presented as mean ± SEM (n=4-5).  
115 
 
 Mature adipocyte isolation and ex vivo analysis of insulin signaling  
Visceral adipose tissue was minced and digested in Hank’s Balanced Salt 
Solution (HBSS; Cat. No. 21-022-CM, Corning®) digestion buffer containing 1 
mg/mL collagenase II, 1% BSA and 100 mM HEPES for 40 min at 37oC. After 
passing through a 250 μm nylon mesh, the stromal cells and mature adipocytes 
were separated by centrifuging at 1,500 x g for 5 min at 4oC. For ex vivo 
analysis of insulin signaling, the mature adipocytes were collected and 
stimulated with or without 100 nM insulin in Dulbecco’s Modified Eagle 
Medium/Nutrient F-12 Ham (DMEM/F12; Cat. No. 16777-133, VWR International) 
for 15 min, followed by cell lysis in Radio-Immunoprecipitation Assay (RIPA; Cat. 
No. 9806, Cell Signaling) buffer containing a protease/phosphatase inhibitor 
cocktail (Cat. No. 5872S, Cell Signaling).  
Bone marrow isolation and macrophage differentiation  
Bone marrow-derived macrophages (BMDMs) were obtained as 
described previously.159 After red blood cell lysis (Table A-4), bone marrow cells 
were seeded at 2 × 106 cells/mL with Iscove’s Modified Dulbecco’s Medium 
(IMDM; Cat. No. 16777-182, VWR International) medium containing 10% FBS 
and 15% L929 culture supernatant as a source of granulocyte macrophage 
colony-stimulating factor (GM-CSF) for differentiation of bone marrow cells to 
monocytes. After 7 days, the formation of mature monocytes was evaluated by 
flow cytometry using antibodies against CD11b and F4/80 cell surface antigens. 
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 Macrophage polarization analysis  
Bone marrow derived macrophages were stimulated by 
lipopolysaccharide (LPS; 100 ng/mL) for M1 activation or IL-4 (20 ng/mL) for M2 
activation. To test the dosage effects of IFNT, BMDMs were treated with IFNT at 
10,000, 5,000, or 1,000 anti-viral units (AVU)/mL for 48 h in the presence of LPS 
or IL-4 (Figure 4.2). After 48 h of stimulation, BMDMs were examined for 
activation of expression of associated surface antigens CD69, CD80, and CD86 
using flow cytometry. 
 
Figure 4.2 Dosage effect of interferon tau (IFNT) on macrophage 
polarization. Bone marrow-derived macrophages (BMDMs) were stimulated 
with lipopolysaccharide (LPS, 100 ng/mL) or interleukin 4 (IL4, 20 ng/mL). In 
addition, BMDMs were treated with IFNT at 1,000 (T1), 5,000 (T2), 10,000 (T3), 
or 0 anti-viral units (AVU)/mL. After 48 hours, the surface makers CD69, CD80, 
and CD86 of BMDMs by were analyzed using flow cytometry to reveal significant 
effects of treatment. Data are presented as mean ± SEM (n=3). *P<0.05, 
**P<0.001. MFI, medium fluorescence intensity.  
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 Flow cytometry analysis  
The Vascular stromal cells (VSC) of VAT and BMDMs were stained with 
fluorescence-conjugated antibodies to detect cell lineages in VAT or their 
activation. B cells were detected with antibodies against cell surface antigens 
B220 (Cat. No. 48-0452-82, eBioscience), CD19 (Cat. No. 17-0193-82, 
eBioscience), CD5 (Cat. No. 11-0051-82, eBioscience) and CD43 (Cat. No. 12-
0431-82, eBioscience); T cells were detected with antibodies against cell surface 
antigens CD4 (Cat. No. 11-0041-82, eBioscience) and CD8 (Cat. No. 17-0081-
82, eBioscience); macrophage subtypes and activation of macrophages were 
detected using antibodies against cell surface markers F4/80 (Cat. No. 11-4801-
82, eBioscience), CD11b (Cat. No. 45-0112-82, eBioscience), CD206 (Cat. No. 
141706, Biolegend), CD11c (Cat. No. 12-0114-82, eBioscience), CD80 (Cat. No. 
17-0801-82, eBioscience), CD69 (Cat. No. 45-0691-82, eBioscience), and CD86 
(Cat. No. 11-0862-82, eBioscience). Phosphorylated signal transducers and 
activators of transcription 1 (STAT1; Cat. No. 612564, BD Biosciences) and 
STAT3 (Cat. No. 557814, BD Biosciences) of BMDMs were detected using an 
intracellular staining assay. Flow cytometry analysis was performed using Accuri 
C6 (BD Bioscience), and results were analyzed using Flowjo or Accuri C6 
software (BD Bioscience).  
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 Immunohistochemistry  
Tissues collected from HFD-fed mice were fixed and stained with 
antibodies against cell surface markers F4/80 (Cat. No. ab6640, abcam), B220 
(Cat. No. ab10558, abcam), and CD3 (Cat. No. ab16669, abcam) to detect 
macrophages, B cells, and T cells, respectively. Immunoglobulin (IgG) protein 
was used as the negative control. Images were captured using a Zeiss Stallion 
Dual Detector Imaging System with Intelligent Imaging Innovations Software 
(Carl Zeiss). 
Western blotting  
After homogenization of VATs using a BeadBugTM microtube 
homogenizer (Benchmark Scientific), total protein was extracted from VAT 
homogenate using RIPA buffer, and protein concentrations were determined 
using the Bradford assay. Proteins were separated on PROTEAN® TGX Stain-
FreeTM Precast Gel (Cat. No. 456-8044, Bio-Rad) and transferred to a 
polyvinylidene fluoride (PVDF) membrane followed by detection of the 
respective antigens using the appropriate antibodies. Activation of the NFκB 
pathway in adipose tissues was evaluated using antibodies against p65 (Cat. No. 
4764, Cell Signaling) and phosphorylated p65 (Pp65; Cat. No. 3033, Cell 
Signaling).  
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 Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) 
analysis  
Total RNA was extracted from adipose tissues or BMDMs using the Trizol 
extraction protocol according to the manufacturer’s instructions. Gene 
expression analysis was performed using the iScript One-Step RT-PCR kit with 
SYBR Green (Cat. No. 170-8893, Bio-Rad) on Bio-Rad CFX384 (Bio-Rad). The 
data presented correspond to the mean of 2-ΔΔCt from at least three independent 
experiments after being normalized to β-actin.  
Bio-Plex protein expression assay  
The concentrations of IL-1β, TNF-α, IL-6, IL-10, and chemokine (C-C 
motif) ligand 2 (CCL2) in plasma were determined using Bio-PlexTM Cytokine 
Assay (Cat. No. M60-009RDPD, Bio-Rad). Concentrations of insulin in plasma 
were determined using the Bio-Plex Pro Mouse Diabetes Insulin set (Cat. No. 
171-G7006M, Bio-Rad). The levels of total (Cat. No. 171-V60007M, Bio-Rad) 
and phosphorylated (Cat. No. 171-V50011M, Bio-Rad) JNK, and total (Cat. No. 
171-V60001M, Bio-Rad) and phosphorylated (Cat. No. 171-V50001M, Bio-Rad) 
Akt in mature adipocytes were determined using the Bio-Plex Cell Signaling 
Magnetic Assays (Bio-Rad). These Bio-Plex assays were performed using the 
Bio-Plex MAGPIXTM multiplex reader (Bio-Rad). Results were analyzed using 
Bio-Plex Data ProTM software (Bio-Rad).  
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 Data and statistical analyses  
Results are expressed as means ± SEM. Each data point derived from 
qRT-PCR assays represents an average of two technical replicates, and data 
were averaged over independently replicated experiments (n=3-4 independently 
collected samples) and analyzed using the Student’s t test. The overall group-
effect was analyzed for significance using two-way ANOVA and the Bonferroni 
post-test for each factor at each individual time. Data analyses were performed 
using Graphpad Prism version 6.0 software. A value of P<0.05 was considered 
statistically significant. 
Results 
Interferon tau alleviates obesity-induced insulin resistance 
To evaluate the effects of IFNT on obesity-associated inflammation and 
insulin resistance, we adopted a diet-induced obese mouse model. An effective 
IFNT dose was chosen based on previous studies.227 After 12 weeks feeding, 
IFNT treatment did not significantly affect body weight gain or food intake in 
either the HFD or LFD groups (Figure 4.3A, B). However, compared to the 
control HFD mice (HFD-Control mice), IFNT treatment (HFD-IFNT mice) 
decreased hyperglycemia and concentrations of insulin in blood (Figure 4.3C). In 
addition, HFD-IFNT mice had lower concentrations of glucose and insulin in 
blood after 16-h of fasting compared to the HFD-Control mice (Figure 4.3C). To 
evaluate the effects of IFNT on insulin sensitivity, mice were subjected to 
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 glucose and insulin tolerance tests. Mice were fasted for 16 h and then injected 
with a single dose of glucose (2 mg of glucose per gram body weight) or insulin 
(1 U of insulin per kg body weight) followed by determination of concentrations 
of blood glucose at various time points (Figure 4.3D, E). With LFD mice, IFNT 
treatment did not alter concentrations of glucose or insulin in plasma; whereas 
HFD-IFNT mice had lower concentrations of glucose in plasma than HFD-
Control mice (Figure 4.3D, E). Collectively, these results suggest that IFNT 
improves obesity-associated glucose metabolism and insulin sensitivity. 
 
Figure 4.3 Interferon tau (IFNT) alleviates insulin resistance in mice fed a 
high-fat diet (HFD). A and B, Body weight and food intake of mice were 
monitored during a 12-week feeding period (n=9-10). C, Concentrations of 
glucose and insulin in plasma of control or IFNT-treated mice fed a HFD or 
fasted for 16 h were less than that of the HFD control mice but not in the mice 
fed a low-fat diet (LFD). Results of glucose tolerance test (D) and insulin 
tolerance test (E) indicated that IFNT treatment improved the insulin sensitivity 
of HFD mice (n=6). Data are presented as mean ± SEM. *P<0.05, **P<0.001, 
***P<0.0001.  
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 Interferon tau alleviates obesity-associated inflammation 
There is compelling evidence for causal effects of obesity-associated 
chronic inflammation, especially in adipose tissues of obese individuals, and the 
pathogenesis of systemic insulin resistance.80 Although HFD-IFNT and HFD-
Control mice had similar degrees of adiposity (Figure 4.4A), IFNT treatment 
suppressed activation of NFκB as evidenced by lower p65 phosphorylation and 
JNK pathway activity particularly decreased abundance of phosphorylated-JNK 
in VAT of HFD mice (Figure 4.4B, C). In addition, HFD-IFNT mice displayed 
lower levels of proinflammatory cytokines, namely IL-1β, IL-6 and TNF-α, and 
increased expression of the anti-inflammatory cytokine IL-10 in adipose tissue 
compared to HFD-Control mice (Figure 4.5A). However, the expression of CCL-
2 in adipose tissues isolated from HFD mice was not affected by IFNT treatment 
(Figure 4.5A). Expression of adiponectin, an adipokine negatively associated 
with obesity, was induced by IFNT treatment in HFD mice compared to the 
control group (Figure 4.5A).  
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 We also detected decreased concentrations of CCL2 and TNF-α and 
elevated concentrations of IL-10 in plasma of HFD-IFNT mice compared to HFD-
Control mice (Figure 4.5B). We further determined the impact of IFNT treatment 
on the insulin signaling pathway in adipose tissues of HFD mice. In the ex vivo 
analysis of insulin signaling, we detected an increase in the abundance of 
phosphorylated Akt protein in isolated mature adipocytes treated with insulin 
compared to that in mature adipocytes from mice that were not treated with 
insulin. This result indicates that insulin successfully activated the intracellular 
insulin signaling pathway in the isolated mature adipocytes. Interestingly, total 
Akt protein and its insulin-responsive phosphorylation were both greater in 
mature adipocytes isolated from HFD-IFNT mice than HFD-Control mice (Figure 
4.5C). Taken together, our results suggest that IFNT treatment effectively 
modulates obesity-associated insulin resistance at least by suppressing tissue 
inflammation.  
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Figure 4.4 Interferon tau (IFNT) reduces obesity-associated adipose tissue 
inflammation. A, Visceral adipose tissues (VAT) weight and adiposity of mice 
after 12-week HFD feeding were not affected by treatment with IFNT. B, Nuclear 
factor-κB (NFκB) activation in VAT of mice fed a HFD was reduced by IFNT 
treatment based on results from western blotting with antibodies against p65 and 
phosphorylated p65 (Pp65; n = 3). C, control; T, IFNT. C, Activation of c-Jun N-
terminal kinase (JNK) signaling pathway in VAT of mice fed a HFD was 
assessed by measuring fluorescent-labeled beads conjugated with antibodies 
against total JNK (tJNK) and phosphorylated JNK (phospho JNK) using the Bio-
Plex® MAGPIXTM multiplex reader. Results indicated that IFNT treatment 
significantly reduced the activation of JNK signaling in VAT of obese mice. MFI, 
medium fluorescence intensity. Data are presented as mean ± SEM. *P<0.05. 
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Figure 4.5 Oral administration of interferon tau (IFNT) alters the cytokine 
profile and insulin signaling. A, Expression of genes encoding interleukin 1 
beta (IL-1β), IL6, and tumor necrosis factor alpha (TNFα) was inhibited, while 
expression of IL10 and adiponectin increased in response to treatment with 
IFNT. B, Concentrations of IL-1β, IL-6, TNF-α, CCL2, and IL-10 in plasma of 
mice fed a high fat diet (HFD) were measured using the Bio-PlexTM Cytokine 
Assay (Bio-Rad). The results indicated that IFNT treatment decreased 
concentrations of CCL2 and TNFα but increased IL10, compared to the control. 
C, Adipose tissue insulin signaling. After 16-h fasting, mature adipocytes were 
collected from VAT and treated with insulin (100 nM) for 15 min. Total AKT 
(tAKT) and phosphorylated AKT (pAKT) protein in adipocytes increased in 
response to IFNT, but in a proportional manner so that the ratio was not different 
as determined using Bio-Plex Cell Signaling Magnetic Assays (Bio-Rad). Data 
are presented as mean ± SEM. *P<0.05. 
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 Interferon tau regulates macrophage activation in adipose tissues of HFD 
mice 
To further understand the impact of IFNT on adipose tissue immune cell 
populations that are major contributors to adipose tissue inflammatory status, we 
examined the relative proportions of T cells, B cells and macrophages in stromal 
cells of VAT from HFD-IFNT and HFD-Control mice. We first performed 
immunohistochemical staining on VAT isolated from both HFD-IFNT and HFD-
Control groups with antibodies against F4/80 (macrophages), B220 (B cells) and 
CD3 (T cells). The results indicated that total numbers of macrophages, B cells 
and T cells infiltrated into VAT are comparable in HFD-IFNT and HFD-Control 
mice (Figure 4.6A). This was confirmed by flow cytometry assays with the same 
set of antibodies. Consistent with results of immunohistochemical staining, the 
proportions of total macrophages (F4/80+CD11b+), B cells (B220+) and T cells 
(CD4+ or CD8+) were not significantly different between IFNT treated and control 
mice on either the HFD (Figure 4.6B) and the LFD (Figure 4.7). Surprisingly, the 
distribution of macrophage subpopulations, i.e. M1 and M2 macrophages, was 
significantly altered by IFNT treatment. Compared to the HFD-Control mice, 
HFD-IFNT mice displayed dramatically decreased proinflammatory M1 
macrophages (F4/80+CD11b+CD206-CD11c+; Figure 4.6C) and a significant 
increase in anti-inflammatory M2 macrophages (F4/80+CD11b+CD206+CD11c-; 
Figure 4.6C) which suggests a regulatory role for IFNT in macrophage 
polarization.  
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Figure 4.6 Interferon tau (IFNT) regulates macrophage activation in 
adipose tissues of mice fed a high fat diet (HFD). A, Sections of adipose 
tissue from mice fed a HFD mice were stained with antibodies against F4/80, 
B220 and CD3 for macrophages, B cells and T cells, respectively. The results 
suggested that IFNT treatment had minimal effects on the infiltration of these 
immune cells into visceral adipose tissue (VAT). B, Macrophage (M), B cell (B), 
CD4+ T cell (T4) and CD8+ T cell (T8) infiltration into VAT of mice fed a HFD was 
not affected by IFNT based on flow cytometry analyses using antibodies against 
F4/80, CD11b, B220, CD4 and CD8. C, Macrophage subtypes in visceral fat 
stromal cells (VSC) of VAT were analyzed by flow cytometry using antibodies 
against F4/80, CD11b, CD11c and CD206. The results indicated a decrease in 
M1 macrophages and an increase in M2 macrophages after IFNT treatment. 
Data are presented as mean ± SEM. *P<0.05, **P<0.001, ***P<0.0001.  
128 
 
  
Figure 4.7 The infiltration of immune cells into adipose tissues of mice fed 
a low fat diet (LFD). A, Macrophage (M), B cells (B), CD4+ T cells (T4) and 
CD8+ T cells (T8) in visceral fat stromal cells (VSC) of visceral adipose tissues 
(VATs) of mice fed a LFD were not affected by treatment with IFNT based on 
results from flow cytometry analyses using antibodies against F4/80, CD11b, 
B220, CD4 and CD8. B, The M2 macrophage subtype VSC of VATs of mice fed 
a LFD was not affected by IFNT treatment based on flow cytometry analyses 
using antibodies against F4/80, CD11b, CD11c and CD206. Data are presented 
as mean ± SEM (n=3-4). 
 
 
Interferon tau modulates macrophage polarization  
Given the distinct shift in activation status of adipose tissue macrophages 
in vivo, we further evaluated the effects of IFNT on macrophage polarization 
using a well-established in vitro model.159 Bone marrow-derived macrophages 
were treated with IFNT at various dosage in the presence of LPS (100 ng/mL) 
for M1 activation or IL-4 (20 ng/mL) for M2 activation and activation of 
associated surface antigens was determined using flow cytometry assays. M2 
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 macrophages (IL-4 treatment) displayed a significantly enhanced activation 
pattern as judged by stronger induction of surface markers CD69, CD80, and 
CD86 at 48 h after stimulation (Figure 4.8A). In contrast, activation of M1 
macrophages induced by LPS treatment was significantly stalled in the presence 
of IFNT resulting in the left shift of surface marker levels (Figure 4.8B). We 
further examined the cytokine production profiles in these M1 and M2 
macrophages using qRT-PCR analysis. As expected, IFNT significantly 
suppressed expression of proinflammatory cytokines IL-1β and TNF-α by 
BMDMs in response to LPS stimulation compared to control BMDMs (Figure 
4.8C, D). In addition, cells also displayed a slight increase in IL-10 upon IL-4 
stimulation in the presence of IFNT (Figure 4.8E). PPARγ is a key regulator that 
suppresses proinflammatory M1 and promotes anti-inflammatory M2 activation. 
Interestingly, IFNT did not affect IL-4-dependent PPARγ expression in M2 
macrophages, but IFNT significantly increased PPARγ expression in M1 
macrophages (Figure 4.8F), which suggests a potent inflammatory suppressing 
impact of IFNT on macrophage polarization. 
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Figure 4.8 Inteferon tau (IFNT) modulates macrophage polarization and 
cytokine profiles. The activation-related surface makers CD69, CD80, and 
CD86 of bone marrow derived macrophages (BMDM) were analyzed using flow 
cytometry after 48-h treatment with interleukin 4 (IL-4, 20 ng/mL; A) or 
lipopolysaccharide (LPS, 100 ng/mL; B) (n=3). The BMDMs were treated with 
IFNT at 5,000 antiviral units (AVU)/mL. The expression of cytokines IL-1β (C), 
TNF-α (D) and IL-10 (E) and peroxisome proliferator-activated receptor γ 
(PPARγ) (F) in BMDMs activated in the presence of IFNT (black bars) were 
analyzed by qRT-PCR (normalized to β-actin, n=3) and compared to activated 
BMDMs with no IFNT treatment (white bars). The results indicated that IFNT 
treatment promotes M2 activation but suppresses M1 activation of macrophages. 
Data are presented as mean ± SEM. *P<0.05, **P<0.001, ***P<0.0001. MFI, 
medium fluorescence intensity.  
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 To understand the mechanism of IFNT action in regulating macrophage 
polarization, we examined signaling pathways mediated by type I interferon 
receptors in activated macrophages. We found that the expression of type I 
interferon receptor (IFNAR) was not affected by IFNT treatment in activated 
BMDMs (Figure 4.9). However, IFNT significantly enhanced STAT3 activation 
upon IL-4 stimulation as evidenced by significantly elevated phosphorylated 
STAT3 protein detected by intracellular staining assays followed by flow 
cytometric analysis (Figure 4.10A). Alternatively, type I interferons can exert 
anti-inflammatory functions through inducing activation of interferon-stimulated 
gene factor-3 (ISGF3) complex, which includes STAT1, STAT2, and interferon 
regulatory factor 9 (IRF9). In M2 macrophages, activation of STAT1 was 
increased by IFNT compared to the control (Figure 4.10B). In LPS-stimulated 
BMDMs, IFNT did not affect the phosphorylation status of STAT1 or STAT3 
(Figure 4.10A, B). In addition, the abundance of IRF9 was significantly 
decreased in M1 macrophages, but increased in M2 macrophages in response 
to IFNT (Figure 4.10C). Thus, these results suggest that IFNT may modulate 
macrophage polarization primarily through controlling activation of ISGF3 
complex and STAT3 pathway. 
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Figure 4.9 Effect of interferon tau (IFNT) on expression of type I interferon 
receptor in bone marrow derived macrophages (BMDMs). The abundance of 
type I interferon receptor in BMDM was not affected by IFNT based on results of 
qRT-PCR analysis after treatment for 48-hours with lipopolysaccharide (LPS, 
100 ng/mL) or interleukin 4 (IL4, 20 ng/mL; n=3) with or without IFNT at 5,000 
AVU/mL. Data are presented as mean ± SEM. 
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Figure 4.10 Interferon tau (IFNT) induces activation of STAT1 and STAT3 in 
bone marrow derived macrophages (BMDMs). A and B, The phosphorylation 
of signal transducer and activator of transcription 3 (pSTAT3) and pSTAT1 in 
BMDMs was increased in response to IFNT as measured by flow cytometry after 
90-min of lipopolysaccharide (LPS, 100 ng/mL) or interleukin 4 (IL-4, 20 ng/mL) 
stimulation (n=3). C, The expression of interferon regulatory factor 9 (IRF9) was 
inhibited by IFNT after cells were exposed for 48-h to LPS, but increased in cells 
after 48-h stimulation by IL4 (n=3). Data are presented as mean ± SEM. *P<0.05, 
**P<0.001. 
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 Discussion 
Adipose tissue inflammation is a major contributor to the pathogenesis of 
obesity-associated insulin resistance.5,80,139 Using a diet-induced obesity model, 
we observed a significant increase in inflammation in both adipose tissue and in 
the systemic circulation of obese mice that was accompanied by exacerbated 
insulin resistance. This is consistent with previous reports and confirms the 
direct correlation between tissue inflammation with obesity-associated insulin 
resistance. Thus, results of our research provided a new set of evidence to 
support the development of therapeutic strategies with anti-inflammatory agents 
to treat patients with obesity-induced insulin resistance and subsequent type 2 
diabetes. Type I interferons exert profound anti-inflammatory effects through 
modulating immune cell functions.218 However, patients treated with IFNA and 
IFNB, two of the available interferon treatment options, often display severe high 
fever, as well as damage to liver and kidney functions.221,222,228 Such adverse 
effects greatly inhibit the adoption of type 1 interferons that may have beneficial 
effects. Compared to IFNA and IFNB, IFNT displays similar immunomodulatory 
functions, but it has low cytotoxicity even at higher dosages, and can provide a 
new option to treat obesity-induced insulin resistance and autoimmune 
disorders.134,224  
Type I interferons share high similarities among their members in both 
primary nucleotide coding and protein folding structure.223 Structural analysis 
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 demonstrated that IFNT binds type I interferon receptors to activate type I 
interferon intracellular signaling pathways that alter immune status.229 This was 
confirmed in our study using an in vitro culture system. IFNT-treated BMDMs 
displayed a significantly suppressed inflammatory response to LPS 
accompanied by decreased production of IL-1β and TNF-α. This effect is 
partially mediated by suppressing the ISGF3 pathway. In addition, IFNT 
significantly enhanced the anti-inflammatory response, namely activation of M2 
macrophages. Accordingly, decreased expression of IL-1β was observed in 
BMDMs stimulated with IL-4 in the presence of IFNT. Our in vivo results further 
confirmed the anti-inflammatory effects of IFNT in adipose tissues, as evidenced 
by suppression on inflammatory pathways and production of proinflammatory 
cytokines.  
Given the potent anti-inflammatory effects of IFNT in vivo, it is not 
surprising that IFNT ameliorated insulin resistance in the obese mice. IFNT 
administration did not affect body weight gain or adiposity of obese mice, or 
metabolic status of adipose tissues and liver of obese mice (Figure 4.11), but 
there was a decrease in concentrations of triglycerides in plasma from HFD-
IFNT mice (Figure 4.12). These results are not consistent with results of a 
previous study with Zucker diabetic fatty rats (ZDF) in which oral IFNT reduced 
white fat mass; however, the results of the present study and that with the ZDF 
rats are consistent in that IFNT enhanced the anti-inflammatory state in both 
models.227 The lack of effect of IFNT on white fat mass may be due to 
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 differences in animal models and length of IFNT treatment as the ZDF rats were 
treated from 4 to 12 weeks of age. Intriguingly, the composition of infiltrated 
immune cells, especially the macrophage subtypes, in adipose tissues was 
significantly altered upon IFNT treatment. The overall adipose tissue immune 
cells including T cell, B cell and macrophage populations in the mice treated with 
IFNT were comparable to the control mice, suggesting that IFNT treatment did 
not affect immune cell recruitment, which was concomitant with unchanged 
expression of CCL2 in adipose tissues from IFNT-treated HFD and control mice. 
However, adipose tissue inflammation was significantly suppressed by IFNT 
treatment as evidenced by decreased expression of proinflammatory cytokines, 
which was associated with increased Akt activation upon insulin stimulation. This 
is partially attributed to the shift of adipose tissue macrophage status resulting in 
more M2 than M1 macrophages. The M2 macrophages exert anti-inflammatory 
effects in the tissue microenvironment including regulation through increased 
secretion of anti-inflammatory cytokines, including IL-10.66 We observed greater 
abundance of IL-10 in HFD mice treated with IFNT. Results of a previous study 
suggest that type I interferons act through either the ISGF3 complex or STAT3 in 
immune cells.218,219 Our results suggested that IFNT functions through the 
ISGF3 complex in macrophages and also has a significant effect to increase 
STAT3 phosphorylation, resulting in significantly enhanced production of IL-10. 
Further understanding of the mechanism of IFNT action in mitigating obesity-
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 associated symptoms and its potential impact on other immune cell activation 
await further investigations.  
 
 
Figure 4.11 The effects of interferon tau (IFNT) on lipogenesis, 
mitochondrial, or lipolysis of adipose tissues and liver of mice fed a high 
fat diet (HFD). The expression of key regulators for lipogenesis, mitochondrial 
function, lipolysis was measured in the adipose tissues (upper panel) and liver 
(lower panel) collected from mice fed a HFD mice or a HFD and treated with 
IFNT mice was not affected by IFNT based on qRT-PCR analyses normalized to 
β-actin. Data are means ± SEM, n=3. ACC, acetyl-CoA carboxylase; FAS, fatty 
acid synthetase; SCD1, stearoyl-CoA desaturase-1; PGC1β, peroxisome 
proliferator-activated receptor gamma, coactivator 1 beta; CPT1, carnitine 
palmitoyltransferase 1; HSL, hormone-sensitive lipase; G6pase, glucose 6-
phosphatase; PEPCK, phosphoenolpyruvate carboxykinase.  
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Figure 4.12 The effect of interferon tau (IFNT) on concentration of 
triglyceride in plasma of mice fed a high fat diet (HFD). Concentrations of 
triglyceride in plasma were decreased (P<0.01) in mice on a HFD that were 
treated with IFNT or fasted for 16 h. Data are presented as mean ± SEM. 
 
In summary, results of our study demonstrate that IFNT is a potent 
regulator for obesity-associated insulin resistance and tissue inflammation that is 
accounted for partially by effects of IFNT to control adipose tissue macrophage 
polarization. Given the low cytotoxicity of IFNT compared to other members of 
the type I interferon family, results of our study provide the first evidence to 
support the potential application of IFNT to mitigate obesity-associated 
syndromes including various autoimmune diseases.  
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 CHAPTER V 
SUMMARY 
Chronic low grade inflammation in adipose tissue of obese individuals is a 
causal factor in the pathogenesis of obesity-associated diseases, including type 
2 diabetes and cardiovascular diseases. Dramatic increases in immune cells in 
visceral adipose tissues of obese individuals primarily display proinflammatory 
profiles characterized by elevated concentrations of inflammatory cytokines and 
systemic insulin resistance. However, the mechanisms regulating functions of 
immune cells in adipose tissue niches in response to obesity are poorly 
understood.  
During the development of obesity, B cells become a major immune cell 
component in visceral fat pad and exert profound impacts on the adipose tissue 
functions. In this thesis study, I have demonstrated that miR-150, a B cell 
specific regulatory microRNA, is a critical modulator of the pathogenesis of 
chronic tissue inflammation and insulin resistance associated with obesity, which 
are major contributors to metabolic syndrome and development of type 2 
diabetes and other cardiovascular complications. miR-150 controls B cell 
functions and their cell-cell interaction with other immune cells through 
simultaneous targeting of multiple targets Elk1, Etf1, and Myb. These miR-150 
target genes can exert a potent impact on the BCR signaling network governing 
adipose tissue B cell function, which can, in turn, change the adipose tissue 
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 niche and its function. Further investigations regarding the mechanisms of action 
of miR-150 and B cells will provide important information toward development of 
therapeutic strategies to alter microRNAs and modulate B cells to treat obesity-
associated complications. 
In the adipose tissue, the composition of ATMs with polarized activation 
status is critical for maintaining adipose tissues homeostasis. Thus, it is critical 
to understand the mechanisms underlying the activation of ATMs. In this thesis 
study, I have showed that the PPARγ-miR-223 regulatory axis is critical for 
modulating the activation status of ATMs and subsequent adipose tissue 
inflammation and insulin sensitivity. miR-223 is a PPARγ-induced genes during 
the M2 responses. miR-223 and its network involving target genes Rasa1 and 
Nfat5 act as the critical downstream components of the PPARγ-mediated cell 
signaling pathway that regulates activation of adipose tissue macrophages. 
Furthermore, identification of novel miR-223 target genes Nfat5 and Rasa1 in 
this context provides new gene targets for development of drugs with the 
potential to mitigate obesity-related diseases. 
The results of last study demonstrate that interferon tau is a potent 
regulator for obesity-associated insulin resistance and tissue inflammation that is 
accounted for partially by effects of interferon tau to control adipose tissue 
macrophage polarization. Further study demonstrates that IFNT functions 
through the ISGF3 complex in macrophages and also has a significant effect to 
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 increase STAT3 phosphorylation, resulting enhanced M2 responses. Given the 
low cytotoxicity of interferon tau compared to other members of the type I 
interferon family, results of this study provide the first evidence to support the 
potential application of interferon tau to mitigate obesity-associated syndromes 
including various autoimmune diseases. 
Collectively, the findings from these thesis studies will open a window to 
the development of novel therapeutic strategies to mitigate obesity-related 
diseases. 
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 APPENDIX 
Table A-1 High-fat diet formula 
Nutrient  % kcal% 
Protein  26.2 20 
Carbohydrate  26.3 20 
Fat  34.9 60 
 Total kcal/gm 5.24 100 
Ingredient  gram kcal 
Casein, 30 mesh  200 800 
L-cystine  3 12 
Maltodextrin 10  125 500 
Sucrose  68.8 275.2 
Cellulose, BW200  50 0 
Soybean oil  25 225 
Lard*  245 2205 
Mineral mix 
S10026 
 10 0 
Dicalcium 
phosphate 
 13 0 
Calcium carbonate  5.5 0 
Potassium citrate, 
H2O 
 16.5 0 
Vitamin mix 
V10001 
 10 40 
Choline bitartrate  2 0 
FD&C Blue Dye#1  0.05 0 
Total, gram  773.85 4057 
*Typical analysis of cholesterol in lard = 0.72 mg/gram 
Cholesterol (mg)/4057 kcal = 216.4 
Cholesterol (mg)/kg = 279.6 
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 Table A-2 Low-fat diet formula 
Nutrient  % kcal% 
Protein  19.2 20 
Carbohydrate  67.3 70 
Fat  4.3 10 
 Total kcal/g 3.85 100 
Ingredient  gram kcal 
Casein, 30 mesh  200 800 
L-cystine  3 12 
Corn starch  315 1260 
Maltodextrin 10  35 140 
Sucrose  350 1400 
Cellulose, BW200  50 0 
Soybean oil  25 225 
Lard*  20 180 
Mineral mix S10026  10 0 
Dicalcium phosphate  13 0 
Calcium carbonate  5.5 0 
Potassium citrate, H2O  16.5 0 
Vitamin mix V10001  10 40 
Choline bitartrate  2 0 
FD&C Blue Dye#1  0.05 0 
Total, gram  1055.05 4057 
*Typical analysis of cholesterol in lard = 0.72 mg/gram 
Cholesterol (mg)/4057 kcal = 54.4 
Cholesterol (mg)/kg = 51.6 
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 Table A-3 Adipose tissue digestion buffer preparation 
 concentration 
HBSS 1x 
HEPES 20mM 
P/S 0.1 KU/mL 
BSA 0.015 g/mL 
Collagenase II 2 mg/mL 
HBSS, Hank’s Balanced Salt Solution; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid; P/S, penicillin-streptomycin; BSA, bovine serum albumin. 
 
 
 
 
 
Table A-4 Red blood cell lysis buffer 
  
NH4Cl 8.3 gram 
KHCO3 1 gram 
EDTA 37 milligram 
ddH2O 1000 mL 
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 Table A-5 Solutions for chromatin immunoprecipitation assay 
Formaldehyde Solution  Stock buffer 50ml 
50 mM HEPES-KOH pH 7.5 1 M HEPES-KOH pH 7.5 2.5 
Or 50 mM HEPES native Or 1 M HEPES   
100 mM NaCl 5 M NaCl 1 
1 mM EDTA 500 mM EDTA 0.1 
0.5 mM EGTA 500 mM EGTA 0.05 
37% formaldehyde   1.375 
ddH2O   44.975 
 Lysis Buffer 1  Stock buffer 50ml 
50 mM HEPES-KOH pH 7.5 1 M HEPES-KOH pH 7.5 2.5 
140 mM NaCl 5 M NaCl 1.4 
1 mM EDTA 500 mM EDTA 0.1 
10% glycerol 50% glycerol 5 
0.5% NP-40 10% NP-40 2.5 
0.25% Triton X-100 10% Triton X-100 1.25 
1× protease inhibitors 100X PI 0.5 
0.02 M Na-Butyrate 2 M Na-Butyrate 0.5 
ddH2O   37.25 
 Lysis Buffer 2  Stock buffer 50ml 
10 mM Tris-HCl, pH 8.0, 1 M Tris-HCl, pH 8.0 0.5 
200 mM NaCl 5 M NaCl 2 
1 mM EDTA 500 mM EDTA 0.1 
0.5 mM EGTA 500 mM EGTA 0.05 
1× protease inhibitors 100X PI 0.5 
0.02 M Na-Butyrate 2 M Na-Butyrate 0.5 
ddH2O   47.35 
 Lysis Buffer 3  Stock buffer 50ml 
10 mM Tris-HCl, pH 8.0 1 M Tris-HCl, pH 8.0 0.5 
100 mM NaCl 5 M NaCl 1 
1 mM EDTA 500 mM EDTA 0.1 
0.5 mM EGTA 500 mM EGTA 0.05 
0.1% Na-Deoxycholate 5% Na-Deoxycholate 1 
0.5% N-lauroylsarcosine 5% N-lauroylsarcosine 5 
1× protease inhibitors 100X PI 0.5 
0.02 M Na-Butyrate 2 M Na-Butyrate 0.5 
ddH2O   42.35 
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 Table A-5 Continued 
Elution Buffer  Stock buffer 50ml 
50 mM Tris-HCl, pH 8.0 1 M Tris-HCl, pH 8.0 2.5 
10 mM EDTA 500 mM EDTA 1 
1.0% SDS 10% SDS 5 
ddH2O  41.5 
 TE + NaCl:  Stock buffer 50ml 
10 mM Tris-HCl pH 8.0 1 M Tris-HCl, pH 8.0 0.5 
1 mM EDTA 500 mM EDTA 0.1 
50 mM NaCl 5 M NaCl 0.5 
ddH2O   48.9 
 TBS  Stock buffer 50ml 
150 mM NaCl 5 M NaCl 1.5 
10 mM Tris pH8.0 1 M Tris-HCl, pH 8.0 0.5 
1× protease inhibitors   0.5 
0.02 M Na-Butyrate 2 M Na-Butyrate 0.5 
ddH2O  48 
 Elution Buffer ChIP  Stock buffer 50ml 
50 mM Tris-HCl pH8.0 1 M Tris-HCl, pH 8.0 2.5 
10 mM EDTA 500 mM EDTA 1 
1.0% SDS 10% SDS 5 
ddH2O   41.5 
 Low-Salt wash buffer  Stock buffer 50ml 
20 mM Tris-HCl, pH 8.0, 1 M Tris-HCl, pH 8.0 1 
150 mM NaCl 5 M NaCl 1.5 
1 mM EDTA 500 mM EDTA 0.1 
0.5 mM EGTA 500 mM EGTA 0.05 
0.1% SDS 10% SDS 0.5 
1% Triton X-100 10% Triton X-100 5 
ddH2O  41.85 
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Table A-5 Continued 
High-Salt wash buffer  Stock buffer 50ml 
20 mM Tris-HCl, pH 8.0, 1 M Tris-HCl, pH 8.0 1 
500 mM NaCl 5 M NaCl 5 
1 mM EDTA 500 mM EDTA 0.1 
0.5 mM EGTA 500 mM EGTA 0.05 
0.1% SDS 10% SDS 0.5 
1% Triton X-100 10% Triton X-100 5 
ddH2O  38.35 
 
LiCl wash buffer  Stock buffer 50ml 
10 mM Tris-HCl, pH 8.0, 1 M Tris-HCl, pH 8.0 0.5 
0.25M LiCl 5 M LiCl 2.5 
1 mM EDTA 500 mM EDTA 0.1 
0.5 mM EGTA 500 mM EGTA 0.05 
1% Na-Deoxycholate 5% Na-Deoxycholate 10 
1.0% NP-40 10% NP-40 5 
ddH2O   31.85 
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